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Abstract 
In this thesis, fed-batch cultivations for effective production of two tissue engineering related bio-
molecules: polysialic acid (PSA) and human basic fibroblast growth factor (FGF-2) are described.   
The PSA production in Escherichia coli (E. coli) K1 in batch and fed-batch cultivations is 
investigated. Three different cultivation strategies were used, namely batch cultivation, fed-batch 
cultivation with a constant specific growth rate of 0.25 h-1 and fed-batch cultivations with a constant 
glucose concentration of 0.1 g l-1 and 0.05 g l-1. A flow injection analysis (FIA) system supported by 
an extended Kalman filter (EKF) was used for on-line measuring and controlling of the glucose 
concentration in the culture broth. The results demonstrated that compared to the batch cultivation, 
both fed-batch strategies have greatly improved the PSA productivity and acetate formation was 
prevented. The highest level of PSA yield on glucose (0.043 g g-1) was obtained in fed-batch 
cultivation at a constant glucose concentration of 0.05 g l-1 with a final PSA concentration of 
1.35 g l-1 in the reactor. The results from the four cultivation experiments further revealed that PSA 
production was correlated to the specific growth rate of the cells and the optimal specific growth 
rate for PSA production in E. coli K1 was 0.32 h-1.   
A biotechnological process for the effective production of FGF-2 in high quantity and quality is 
presented. Fed-batch cultivations of E. coli BL21 at two constant specific growth rates (0.35 h-1 and 
0.15 h-1) were performed. The higher expression level (42 mg g-1 dry cell) of FGF-2 with higher 
time-space yield of soluble protein (0.056 g l-1 h-1) was achieved by fed-batch cultivation at a 
constant specific growth rate of 0.35 h-1. For the purification, a new combination of cation exchange 
membrane chromatography and heparin-sepharose affinity chromatography was applied. A novel 
anion exchange membrane chromatography was used in the polishing step to remove endotoxins 
and DNAs, yielding ≥ 98 % pure FGF-2 as determined by RP-HPLC. This new process yielded 
about 200 mg of pure FGF-2 from 1.9 l culture broth. A carrier-free formulation was developed for 
the lyophilization and long-term storage of FGF-2 using sucrose as a stabilizer. The purified FGF-2 
was endotoxin-free and demonstrated a high mitogenic activity on mesenchymal stem cell-like cells 
(EC50 = 0.13 ng ml-1) and NIH-3T3 cells (EC50 = 0.10 ng ml-1). It has also been successfully tested 
on neuronal differentiation of PC 12 cells and keeping primate ESC (embryonic stem cell) and 
human iPSC (induced pluripotent stem cell) pluripotent at cooperation institutes, which proved 
purified FGF-2 was suitable for using in cell culture. A preliminary stability test demonstrated that 
lyophilized FGF-2 powder has an average residual water content of 1.90 %. And the freeze-dried 
protein was stable after 17 days storage at 37 °C, 1 month at room temperature or 2 month at 4 °C.  
Keywords: polysialic acid; fed-batch cultivation; human basic fibroblast growth factor 
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Zusammenfassung 
In dieser Arbeit werde Fed-Batch Kultivierungen für die effektive Produktion von zwei Tissue 
Engineering relevanten Biomoleküle: Polysialinsäure (PSA) und menschliche basischer 
Fibroblasten Wachstumsfaktor (FGF-2), beschrieben. 
Die Produktion von PSA in Escherichia coli (E. coli) K1 durch Batch und Fed-Batch 
Kultivierungen wurde untersucht. Drei verschiedenen Fermentationstrategien wurden verwendet, 
nämlich Batch, Fed-Batch mit einer konstanten spezifischen Wachstumsrate von 0,25 h-1 und Fed-
Batch mit konstanten Glucose-Konzentrationen von 0,1 g l-1 oder  0,05 g l-1. Ein Fließ-Injektions-
Analyse (FIA) System mit einem erweiterten Kalman-Filter (EKF) wurde eingesetzt für das on-line 
Monitoring und die Regelung der Glucose Konzentration in der Kulturbrühe. Meine Ergebnisse 
wiesen auf, dass die beiden Fed-Batch Strategien im Vergleich zum Batch die Produktivität von 
PSA erheblich verbessert haben und die Bildung von Acetat eliminiert wurde. Die höchste 
Ausbeute von PSA zu Glucose war 0,043 g g-1, die bei der Fed-Batch Kultivierung mit einer 
konstanten Glucosekonzentration von 0,05 g l-1 erhalten wurde. Dabei betrug die End-
Konzentration von PSA im Reaktor 1,35 g l-1, d.h. die Produktion von PSA ist mit der spezifischen 
Wachstumsrate der Zellen korreliert und die optimale spezifische Wachstumsrate für die 
Herstellung in E. coli K1 beträgt 0,32 h-1. 
Ein komplett neues biotechnologisches Verfahren zur Produktion von FGF-2 mit hoher Quantität 
und Qualität wurde auch in dieser Arbeit erarbeitet. Dazu wurde die  Fed-Batch Kultivierung von 
E. coli BL21 mit zwei unterschiedlichen spezifischen konstanten Wachstumsraten (0,35 h-1 und 
0,15 h-1) durchgeführt. Die höhere Expression von FGF-2 (42 mg g-1 Trockenbiomasse) erfolgte bei 
eine Wachstumsrate von 0,35 h-1. Dabei errichte man eine höhere Raum-Zeit-Ausbeute an 
löslichem Protein (0,056 g l-1 h-1). Eine neue Kombination von Kationenaustauschermembran 
Chromatographie und Heparin-Sepharose Affinitätschromatographie begünstigte die Aufreinigung 
von FGF-2. Außerdem wurde eine neuartige Anionenaustauschermembran Chromatographie als 
Polierschritt zum Entfernen der Endotoxine und DNAs verwendet. Die durch RP-HPLC bestimmte 
Ausbeute des reinen FGF-2 lag über 98 %. Dieses Kosten günstige Verfahren liefert etwa 200 mg 
von reinem FGF-2 aus 1,9 l Kulturbrühe. Eine Träger-freie Formulierung war bereits für die 
Gefriertrocknung und Lagerung von FGF-2 entwickelt worden, dabei war Saccharose als 
Stabilisator eingesetzt. Das aufgereinigte FGF-2 zeigte eine hohe mitogenetische Aktivität in 
mesenchymalen Stammzell-ähnlichen Zellen (EC50 = 0,13 ng ml-1) und NIH-3T3 Zellen (EC50 = 
0,10 ng ml-1). Weitere in unseren Koorperationsinstituten durchgeführte Aktivität-Tests, z.B Testen 
für die neuronale Differenzierung der PC 12 Zellen und der Erhalt der Pluripotenz von Primaten 
ESC (embryonalen Stammzellen) sowie menschliche iPSC (induzierte pluripotente Stammzellen), 
erzielten auch ausgezeichnete Ergebnisse. Darüber hinaus wurde nachgewiesen, dass das 
lyophilisierte FGF-2 Pulver einen durchschnittlichen Restwassergehalt von 1,90 % hat. Deswegen 
kann das gefriergetrocknete Protein stabil bleiben nach der Lagerung von 17 Tagen bei 37 °C, 1 
Monat bei Raumtemperatur oder 2 Monate bei 4 °C. 
Stichworte: Polysialinsäure;  Fed-Batch Kultivierung; menschliche basischer Fibroblasten 
Wachstumsfaktor  
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1. Introduction 
Tissue engineering is a rapidly evolving field which combines the knowledge of biology, 
biochemistry, medicine, material scicence and engineering to develope new biological 
replacements in order to repair, maintain or improve tissue/organ functions (Skalak and 
Fox, 1988). 
In the past 20 years, remarkable progresses were achieved in this relatively “young” area 
(Atala, 2006; Koh and Atala, 2004; Shieh and Vacanti, 2005; Stock and Vacanti, 2001). 
Nowadays, stem cell researches have become an important aspect of tissue engineering 
(Bianco and Robey, 2001; Lanza et al., 2007; Leo and Grande, 2006; Polak and Bishop, 
2006). And finding biodegradable polymers as scaffold materials become another 
significant area (Hutmacher, 2001; Ifkovits and Burdick, 2007; Ma and Elisseeff, 2006; 
Yang et al., 2001, 2002).  
Cytokines play an important role in various cellular processes such as cell proliferation, 
differentiation, migration, adhesion (Babensee et al., 2000; Lee, 2000). Therefore they are 
widely used as supplements in stem cell cultivations. In this thesis a biotechnological 
process for the production of an extensively used cytokine-human basic fibroblast growth 
factor (FGF-2) is described. Additionally, an optimum fed-batch strategy for the production 
of a promising biodegradable scaffold material-polysialic acid (PSA) is also presented. 
For PSA production, batch cultivation, fed-batch cultivations with two different control 
strategies were performed. PSA yields on glucose were compared and the best cultivation 
condition for PSA production was identified. For FGF-2 production, efficient production of 
FGF-2 was achieved by fed-batch cultivation of Escherichia coli BL21 and a new 
purification process was developed using membrane adsorber technology. The purified 
protein was identified to be endotoxin-free and bioactive. It has been successfully tested in 
cultivating PC12 cells, embryonic stem cells and induced pluripotent stem cells, etc. 
The production processes decribed in this thesis support large-scale preparation of PSA and 
FGF-2 at low-cost, thus will be benefical to the furture tissue engineering researches.
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2. Theoretical background 
2.1 Cultivation of Escherichia coli  
Fermentation processes are utilized for the production of various biological products such 
as amino acids, antibiotics, proteins and enzymes. Among all the organisms used in 
fermentation, Escherichia coli (E. coli) is the most commonly used. Since recombinant 
DNA technology emerged in 1970s, E. coli has become the most widely used prokaryotic 
expression system for the production of heterologous proteins. 
The cultivation of E. coli is usually carried out in a stirred tank bioreactor. Air is sparged 
into the medium and well distributed by a mechanical stirrer. In order to maintain suitable 
growth conditions for the cells, temperature, pH value and dissolved oxygen concentration 
in the reactor are controlled. 
2.1.1 Cultivation medium 
Cultivation mediums can be divided into two major types, complex medium and defined 
medium. A complex medium contains some components whose chemical composition is 
unknown, such as yeast extract, beef extract or peptone. The most commonly used complex 
medium for E. coli cultivation is LB medium (Luria-Bertani medium). However, the 
composition of complex media may be different from batch to batch which makes 
cultivation results not reproducible. While in defined medium all the chemical components 
are known. A defined medium usually contains carbon sources, nitrogen sources, trace 
elements and vitamins. The most commonly used carbon source is glucose and ammonium 
salts are often used as nitrogen sources. Trace elements and vitamins are used at very low 
concentrations for the better growth of the cells. Defined medium is often used in high cell 
density cultivation of E. coli.  
2.1.2 Measurement and control 
Common on-line measurements of cultivations including pH value, temperature and 
dissolved oxygen concentration as well as the CO2 and O2 content in the exhaust gas. 
Robust and precise sensors have been developed to monitor these parameters. However, 
many important process variables are still difficult to measure on-line such as biomass 
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concentration, acetate concentration and glucose concentration in the reactor. Therefore, in 
the past two decades, many new approaches were developed for on-line process 
monitoring. 
For example, the use of non-invasive methods such as 2D-fluorescence spectroscopy 
(Lindemann et al., 1998; Marose et al., 1998) and in-situ microscopy (Bittner et al., 1998; 
Joeris et al., 2002) to monitor bioprocesses has been applied. A detailed review see (Marose 
et al., 1999). On-line analytical instruments based on flow injection analysis (FIA) system 
have been developed and tested (Schügerl et al., 1993; Schügerl et al., 1996; Steube and 
Spohn, 1994). Software sensors based on extended Kalman filter (EKF), fuzzy logic, 
adaptive controller and artificial neural network (ANN) have been exploited for on-line 
state estimation of bioprocesses (Chéruy, 1997; Chen et al., 2004; de Assis and Filho, 2000; 
do Carmo Nicoletti et al., 2009). A thorough review is given in (Schügerl, 2001). 
2.1.3 Operation modes 
There are three main cultivation techniques, known as batch, continuous and fed-batch 
operations.  
In batch cultivations, all nutrients are put into the reactor at the beginning of the cultivation 
and cells are harvested at the end of the cultivation.  While in continuous cultivations, fresh 
medium is fed into the reactor at a constant rate (i.e. dilution rate) and meanwhile the 
culture broth is taken out at the same rate. Therefore, the growth rate of the cells can be 
controlled by manipulating the dilution rate.  
Fed-batch cultivations usually starts with an initial batch phase and afterwards growth 
limiting substrates are fed into the bioreactor at a controlled rate. By changing the feed rate, 
cell growth rate can be easily controlled at the desired set point. Using this method, the 
oxygen transfer limitation and acetate formation in batch cultivations could be avoided and 
high cell density in the bioreactor could be achieved. Therefore, fed-batch cultivation has 
been widely used in industrial fermentations.  A typical fed-batch cultivation is shown in 
Fig. 2.1. 
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Fig. 2.1Diagram of a typical fed-batch cultivation.  
2.1.4 Limiting factors in E. coli cultivation 
2.1.4.1 Medium  
E. coli needs various nutrients to support its proper growth, such as carbon, nitrogen, 
phosphorus, sulfur, magnesium, potassium, iron, manganese, zinc and copper (Gunsalus et 
al., 1960). However, most of the medium components become growth inhibitors when their 
concentrations in the medium reach a critical value. For example, glucose at a 
concentration above 50 g l-1, ammonium above 3 g l-1, phosphorus above 10 g l-1, iron 
Biomass concentration
Substrate concentration
Feed rate
Time
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above 1.15 g l-1, magnesium above 8.7 g l-1, copper above 0.0042 g l-1 are known to inhibit 
the growth of E. coli (Riesenberg, 1991). Therefore, cultivations should always start with 
initial nutrients concentrations below the critical values. 
2.1.4.2 Oxygen supply 
Due to the low solubility of oxygen in water, oxygen supply is a common limiting factor in 
E. coli cultivations. Several methods have been developed to increase oxygen supply in a 
bioreactor. For example, increasing air flow rate or stirrer speed, mixing air with oxygen or 
using pure oxygen and pressurizing the reactor (Riesenberg, 1991). Moreover, new air 
separation system using membrane gas separation technology has been developed (Wang et 
al., 1988). This system can convert ambient air into oxygen enriched air with oxygen 
content up to 50 % (Fass et al., 1989). 
2.1.4.3 Acetate formation 
In aerobic conditions, when E. coli is cultivated on excess glucose will cause the excretion 
of acetate into the medium. This glucose induced acetate formation phenomenon is also 
called as bacterial Crabtree effect (Rinas et al., 1989), which could result in up to 15 % of 
glucose being converted into acetate (Holms, 1986). However, acetate concentration above 
2 g l-1 was known to affect cell growth as well as reduce recombinant protein productivity 
(Bauer et al., 1990; Koh et al., 1992; Sakamoto et al., 1994; Turner et al., 1994b). 
As the main by-product of E. coli cultivation, acetate formation during cultivation 
processes has been intensively studied. In 1982, Doelle et al. (1982) observed acetate 
production from excess glucose. Meyer et al. (1984) proposed thresholds for acetate 
formation in chemo-stat cultures with both defined and complex medium. Majewski and 
Domach (1990) predicted that restrictions might exist in the capacity of the oxidation chain. 
Han et al. (1992a) further suggested that limited oxidation capacity of the TCA 
(tricarboxylic acid) cycle might be the reason for acetate formation.  
Many approaches have been developed to avoid acetate accumulation in E. coli cultivations. 
Such as using fed-batch technique to limit glucose supply (Lee, 1996); replacing glucose 
with glycerol (Korz et al., 1995) or fructose (Aristidou et al., 1999); using metabolic 
engineering to change metabolic pathway (Bauer et al., 1990); using dialysis to remove 
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acetate (Märkl et al., 1993; Nakano et al., 1997) and using a probing feeding technology 
(Åkesson et al., 1999).  
2.2 Fed-batch cultivation of E. coli 
Because of the high volumetric yield of the desired product, fed-batch has become the most 
popular technique for high cell density cultivation of E. coli. Simple carbon source feeding 
strategies can be developed based on mathematical models of E. coli growth with limited 
substrate. Thus, demand of substrate by the cells can be easily calculated. 
Other more advanced feeding methods involve the application of direct or indirect feedback 
control systems. Indirect feedback control system utilize feedback signal from the on-line 
measuring of actual cultivation parameters such as pH value and dissolved oxygen 
concentration. The system feed carbon substrate according to the sudden change of these 
paprameters. While in direct feedback control system, the feedback signal is directly come 
from the on-line monitoring of substrate concentrations. By comparing the feedback signal 
with the set point, the system adds feed medium to the reactor in order to keep the substrate 
concentration at the set point. 
Comprehensive reviews of various control strategies for E. coli cultivations are in 
(Konstantinov and Yoshida, 1992; Lee, 1996; Riesenberg and Guthke, 1999; Wlaschin and 
Hu, 2006; Yee and Blanch, 1992). 
2.2.1 Bioprocess models 
Bioprocess models can be divided into four different types. If the model treats all the cells 
independently (i.e. every cell is different), it is a segregated model (Tsuchiya et al., 1966). 
If the model considers all the cells as the same, it is a non-segregated model (Fredrickson et 
al., 1970). Moreover, if the model includes the reactions inside the cells, it is a structured 
model. However, if the model considers the cell as an entirety without internal reactions, it 
is an unstructured model.  
Among all the bioprocess models, unstructured non-segregated models are the simplest. 
They treat the cells as the same and internal reactions inside the cells are not considered. 
The most widely used unstructured non-segregated model is the Monod growth model 
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(Monod, 1949). In this model the cell growth kinetics can be described using specific 
growth rate-µ and Monod substrate saturation constant-Km (Eq. 1.1). 
ߤ ൌ ߤ௠௔௫ ௌ௄೘ାௌ (1.1) 
Here S is the substrate concentration, µmax is the maximum specific growth rate and Km is 
the limiting substrate concentration when half maximum specific growth rate is reached 
(ߤ ൌ ఓ೘ೌೣଶ ). The cell growth can be described as (Eq. 1.2): 
ௗ௑ሺ௧ሻ
ௗ௧ ൌ ߤܺሺݐሻ (1.2) 
And the substrate consumption can be written as (Eq. 1.3): 
ௗௌሺ௧ሻ
ௗ௧ ൌ െ
ఓ௑ሺ௧ሻ
௒೉/ೄ  (1.3) 
Therefore, a fed-batch cultivation carried out in an ideal stirred tank bioreactor could be 
described by the following equations (Eq. 1.4-1.6): 
ௗ௑ሺ௧ሻ
ௗ௧ ൌ
ఓ೘ೌೣௌሺ௧ሻ
௄೘ାௌሺ௧ሻ ܺሺݐሻ െ
௏ሶಷሺ௧ሻ
௏ೃሺ௧ሻ ܺሺݐሻ (1.4) 
ௗௌሺ௧ሻ
ௗ௧ ൌ െ
ఓ೘ೌೣௌሺ௧ሻ
௄೘ାௌሺ௧ሻ 	
௑ሺ௧ሻ
௒೉/ೄ ൅
௏ሶಷሺ௧ሻ
௏ೃሺ௧ሻ ሺܵ଴ െ ܵሺݐሻሻ (1.5) 
ௗ௏ೃሺ௧ሻ
ௗ௧ ൌ ሶܸிሺݐሻ (1.6) 
Where, ܺሺݐሻ – concentration of biomass at time t (g l-1); 
ܵሺݐሻ – concentration of substrate at time t (g l-1); 
ߤ௠௔௫  – maximum specific growth rate (h-1); 
ܭ௠ – Monod substrate saturation constant (g l-1); 
ሶܸிሺݐሻ – feed rate at time t (l h-1); 
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ோܸሺݐሻ – culture volume at time t (l); 
ܵ଴ – substrate concentration of feed solution (g l-1); 
ߤ – specific growth rate (h-1); 
௑ܻ/ௌ – yield coefficient (g g-1). 
Although the real bioreactor is far away from ideal, this model is still useful in fed-batch 
cultivation design and control. 
2.2.2 Control strategies 
A control strategy is used to determine the amount of feed medium to be added into the 
reactor at a specific time. Many control strategies have been developed in order to meet this 
requirement (Johnson, 1987). They can be roughly divided into two types: open-loop and 
closed-loop control strategies. 
2.2.2.1 Open-loop control 
An open-loop control system control the feeding pump directly based on given parameters 
and a process model. However, since there is no feedback the open-loop control system 
does not know whether its control is successful or not. In most fed-batch cultivations with 
open-loop control, the substrate feed rate ሶܸிሺݐሻ is calculated by the process model in order 
to keep a constant specific growth rate of the cells. For Monod model, the substrate feed 
rate could be calculated from Eq. 1.5, by assuming a constant substrate concentration in the 
bioreactor (	ௗௌௗ௧ ൌ 0) (Eq. 1.7): 
ሶܸிሺݐሻ ൌ ߤ௠௔௫ ௌሺ௧ሻ௄೘ାௌሺ௧ሻ 	
௑ሺ௧ሻ
௒೉/ೄ 	
ଵ
ௌబିௌሺ௧ሻ ோܸሺݐሻ (1.7) 
The numerically calculated substrate feed rate could be used for feeding control directly. 
This strategy has been successfully used in various fed-batch cultivations (Jenzsch et al., 
2006; Korz et al., 1995; Paalme et al., 1990).  However, in order to get high quality control, 
initial values given to the Monod model especially initial biomass concentration must be 
precisely determined. Since small deviations of initial biomass concentration at the 
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beginning of the fed-batch phase will lead to significant errors at the end of the cultivation. 
Moreover, the control system can not detect or correct these errors due to the lack of 
feedback. Therefore, closed-loop control system is exploited in order to obtain a more 
accurate and robust control. 
2.2.2.2 Closed-loop control 
A closed-loop control system uses feedback signal from the on-line measurements of 
cultivation parameters for accurate control. The system compares the feedback signal with 
the set point and then adjusts the feeding pump accordingly. 
Many important process variables can be used for indirect feedback control, such as pH 
value (Honda et al., 1998; Lee and Chang, 1993; Sugimoto et al., 1999) and dissolved 
oxygen concentration (Cutayar and Poillon, 1989; Konstantinov et al., 1990; Mori et al., 
1979; Yang and Maa, 1998; Yano et al., 1991). In these strategies, the feed media is added 
when glucose is exhausted as shown by a sudden increase in dissolved oxygen 
concentration or pH value, which is also called DO-stat and pH-stat. However, the 
disadvantage of these strategies is the cultivation conditions are not stable. The cell states 
are kept changing between starvation and glucose availability since the feeding is non-
continuous. Therefore, direct feedback control system was developed. 
Direct feedback control system is more advanced than indirect feedback system. According 
to the feedback of current substrate concentrations in the reactor, the control system can 
calculate the amount of feed media to be delivered to the reactor in order to reach the 
substare set point. This type of control system has already been used in various fed-batch 
cultivations (Horn et al., 1996; Kleman et al., 1991; Sakamoto et al., 1994). However, the 
glucose concentrations in the culture broth are usually very low during the fed-batch phase. 
In most cases they are even lower than the detection limit of exsiting commercial on-line 
measurement devices. Therefore, robust and accurate on-line glucose measurement systems 
are required for high quality control. Direct feedback from on-line monitoring of acetate 
concentrations has also been applied in fed-batch cultivations by Shimizu et al.(1988) and 
Turner et al.(1994a). However, accurate on-line acetate measurement devices are also 
needed.  
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2.2.3 Flow injection analysis (FIA) 
Flow injection analysis (FIA) technique was first introduced by Růžička and Hansen in 
1975. It is based on “the injection of a liquid sample into a moving, nonsegmented 
continuous liquid carrier stream. The injected sample forms a zone, which is then 
transported toward a detector that continuously records the changes in absorbance, 
electrode potential, or other physical parameter resulting from the passage of the sample 
material through the flow cell” (Růžička and Hansen, 1975).  Since that time, this automated 
system has been widely used in various aspects (Stewart, 1981; Trojanowicz, 2000). The 
principles and components of FIA are described in (Růžička and Hansen, 1988). 
Different FIA systems have been developed for the on-line monitoring of glucose 
concentrations. Most of them are based on an enzymatic method using glucose oxidase 
(GOD) to catalyze the oxidation of D-glucose to H2O2 and D-glucono-δ-lactone. The latter 
one is then hydrolyzes to gluconic acid (Eq. 1.8). Thus, either the oxygen consumed in this 
reaction could be measured by an amperometric detector (Kumar et al., 2001; Male et al., 
1997; Schügerl et al., 1991; Van Putten et al., 1996) or GOD is combined with peroxidase 
(POD) which can react with the formed H2O2, afterwards the glucose concentration can be 
measured colorimetrically (Benthin et al., 1992; Garn et al., 1989; Valero et al., 1990). 
Glucose ൅ Oଶ ൅ HଶO ୋ୓ୈሱۛሮ 	Gluconic	acid ൅ HଶOଶ (1.8) 
In our institute, an automated FIA system has been developed for the on-line monitoring of 
bioprocess (Brandt and Hitzmann, 1994; Hitzmann et al., 1996; Hitzmann et al., 1997; 
Hitzmann et al., 1995). This system has been successfully applied in on-line monitoring of 
various cultivations (Umoh et al., 1996; Van Putten et al., 1995; Weigel et al., 1996). 
2.2.4 Extended Kalman filter (EKF) 
In 1960, R.E. Kalman described a recursive method for solving the process state estimation 
problem and afterwards it was named the Kalman filter. Since then, this powerful filter has 
been widely used in various aspects, such as linear state estimation, computer image 
recognition, satellite navigation and radar tracking (Sorenson, 1985). The mathematical 
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algorithm of Kalman filter was well elucidated by (Brown and Hwang, 1992; Jacobs, 1993; 
Kalman, 1960; Maybeck, 1979; Meinhold and Singpurwalla, 1983). 
The extended Kalman filter (EKF) expands the application of Kalman filter into nonlinear 
area.  EKF “can compensate for the missing process data by a prior knowledge about the 
process.  At each individual time step when new measurement data become available, the 
EKF determines a new estimate from the data obtained one step before, the model 
prediction and the value determined from the measurements. The new estimate is a 
weighted average of these three data, where the EKF determines the weights from the 
reliabilities that are attributed to the measurement values, the measurement uncertainties, 
the model equations and the last estimate” (Gnoth et al., 2008). Therefore, the estimated 
values by EKF are closer to the actual values than the original measurement values. A 
detailed formulation of EKF can be found in (Analytic Sciences Corporation. Technical 
Staff and Gelb, 1974; Kopp and Orford, 1963; Lee and Ricker, 1994; Reif and Unbehauen, 
1999).  
EKF has been widely used in fermentation processes (Stephanopoulos and Park, 1991; 
Stephanopoulos and San, 1983), such as yeast cultivation (Bellgardt et al., 1986), E. coli 
cultivation (Dubach and Märkl, 1992; Hilaly et al., 1994) and cultivations of other 
organisms (Ghoul et al., 1991; Náhlík and Burianec, 1988; Weuster-Botz et al., 1997; 
Zhang and Su, 2002) even industrial production process (Wilson et al., 1998). In recent 
years, EKF is combined with fuzzy logic (Simutis et al., 1992), neural network (Liu, 1999), 
etc. for more sophisticated process control.  
In our institute, an EKF control system has been established based on on-line measuring of 
glucose concentration using the FIA system (Hitzmann et al., 2000). It has been 
successfully used in fed-batch cultivation of yeast (Arndt and Hitzmann, 2004; Klockow et 
al., 2008) and E. coli (Arndt et al., 2005; Kleist et al., 2003) at different glucose 
concentration set points. 
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3. Optimization of polysialic acid production using different 
cultivation strategies 
3.1 Introduction 
3.1.1 Sialic acid 
Sialic acid was first isolated from bovine submaxillary mucin as a saccharide-like 
component by Gunnar Blix in 1936. Till now, the sialic acid family has more than 50 
members which are widely distributed in nature (Angata and Varki, 2002).  Sialic acids 
play an important role in the chemical and biological diversity of glycoconjugates (Kelm 
and Schauer, 1997; Schauer, 1985; Schauer et al., 1982) and can also regulate many cellular 
and molecular interactions (Schauer, 2009). Moreover, different cell sialoglycosylation 
patterns could be found during cell development, aging and oncogenesis processes 
(Rosenberg, 1995).  
 
Fig. 3.1 Structure of N-acetyl-neuraminic acid (Neu5Ac). 
 
N-acetyl-neuraminic acid (Neu5Ac, see Fig. 3.1) is the most extensively studied member in 
the sialic acid family. It is also considered to be the origin of other family members 
(Schauer, 1982). Therefore, “sialic acid” is also refers to Neu5Ac in the literature.  
3.1.2 Polysialic acid 
In 1957, Barry and Goebel (1957) first isolated colominic acid from the culture broth of 
E. coli K235. Later, Barry (1958) found that colominic acid was a polymer of  Neu5Ac. 
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Further study revealed that colominic acid was a low-molecular-weight homopolymer of 
Neu5Ac (McGuire and Binkley, 1964). Polysialic acid (PSA) is a high-molecular-weight 
homopolymer which consists of sialic acids with up to 200 residues (Pelkonen et al., 1988; 
Rohr and Troy, 1980). 
3.1.2.1 Structure 
The most common structure of PSA is the Neu5Ac polymer with α2,8-linkage (Fig. 3.2). 
 
Fig. 3.2 Structure of α2,8-linked poly-5-N-acetyl-neuraminic acid. This figure has been adapted 
from Rode et al.(2008). 
3.1.2.2 Biological functions and applications 
PSA is the major macromolecular ingredient found in vertebrate brains (Finne, 1982) and 
plays an important role in the regulation of various cell contact interactions (Acheson et al., 
1991). In the nervous system, PSA participates in various cell processes such as cell 
migration, axonal guidance and synaptogenesis (Bruses and Rutishauser, 2001). Moreover, 
neuronal regeneration could be induced in adult brain when PSA synthesis was reactived 
(El Maarouf et al., 2006). 
PSA is a biodegradable polymer and its degradation products are non-toxic (Gregoriadis et 
al., 1993).  Moreover, it is a biocompatible material and does not evoke immune response 
(Moreno et al., 1985). These properties make it very suitable to be used in drug delivery 
system (Gregoriadis  et al., 2000).  
Most recent studies demonstrate that PSA is a promising biomaterial for cell culture, tissue 
engineering and biomedical applications. Stark et al. (2008) used PSA as coating material 
to cultivate Hep-G2 and PC 12 cells. Same results were obtained comparing to 
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conventional coating materials (e.g.  collagen I, hyaluronic acid and poly-L-lysine). Haile et 
al. (2007) cultivated glial and neuronal cells on PSA, good results were also obtained. Due 
to high solubility in water, PSA could not be used as biomaterial directly. Berski et al. 
(2008) have synthesized a hydrogel based on PSA and tested it as a scaffold material. They 
found this hydrogel can be controllably degraded by endosialidase and it was suitable as 
growth supporting material for PC 12 cells. Steinhaus et al. (2010) immobilized PSA on 
glass surfaces and found that it could aid nerve regeneration. 
3.1.2.3 PSA of E. coli  
 
Fig.3.3 Transmission electron microscopy of E. coli K1. This figure has been adapted from Vimr et 
al.(2004). 
PSA is produced by some bacteria as their capsules, such as Neisseria meningitidis, E. coli, 
group B streptococci, Haemophilus ducreyi and Pasteurella hemolytica (Mizanur and Pohl, 
2008). In E. coli K1, the capsule PSA belongs to the group 2 bacterial capsules, which 
consists of linear homo α2,8-linked Neu5Ac residues (Whitfield, 2006). This capsule also 
covers the bacterial specific antigens and protects the bacteria from being recognized by the 
host immune system (Moxon and Kroll, 1990). The biosynthesis process of PSA in E. coli 
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K1 was well elucidated by Bliss and Silver (1996), Whitfield (2006) and Steenbergen and 
Vimr (2008). The pattern of E. coli K1 capsule is shown in Fig. 3.3. 
3.1.2.4 Production  
In nature, PSA only presents in several materials at a very low level, such as swallow's 
nests, whey from cheese production, chalaza and egg membranes (Kapre and Shaligram, 
2010). Therefore it was mainly produced by microbial fermentation.  
Several groups have studied the production of PSA with different bacterial strains. The 
early studies were mainly focused on optimizing medium and cultivation conditions. 
Orskov et al. (1984) and González-Clemente et al. (1990) found that PSA production was 
temperature regulated. Rodríguez-Aparicio et al. (1988) reported that PSA production in 
bacteria was depended on temperature as well as pH value and aeration of the medium. 
Zhan et al. (2002) cultivated E. coli K235 in batch and fed-batch cultivations with 
controlled pH value of 6.4, a PSA yield of 2,600 mg l-1 was obtained. However, they were 
using expensive sorbitol as carbon source. Liu et al. (2010) cultivated E. coli K235 by 
maintaining a sorbitol concentration around 20 - 40 g l-1 in the medium during the fed-batch 
phase, the final PSA concentration reached 5,399 mg l-1. Kapre and Shaligram (2010) have 
also developed a process for the production and purification of PSA as described in a 
patent.  
In our group, Rode et al. (2008)  have established a biotechnological process for the 
production and purification of long chain PSA in E. coli K1. In this study, we are focusing 
on maximizing the efficiency of PSA production. For this purpose, different cultivation 
strategies were applied for the cultivation of E. coli K1and a comparison of PSA yield on 
glucose was performed. 
This work was cooperated with Jinu John from the group of Bernd Hitzmann at the TCI. 
3.2 Bacterial strain 
A clinical isolated wild type strain E. coli B2032/82 serotype K1was used throughout this 
study. The strain was stored as a 50 % (v v-1) glycerol stock at - 80 °C. 
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3.3 Experiments 
3.3.1 Preculture and medium 
A complex medium (Appendix 6.2.1.1) was used as preculture medium. The preculture was 
prepared by inoculating a glycerol stock into 100 ml medium in a 500 ml shaking flask and 
was subsequently incubated on a rotary shaker at 37 °C, 120 rpm for 10-12 h. Then it was 
directly used to inoculate the bioreactor. A synthetic medium was prepared according to 
Rode et al. (2008) and used for the batch and fed-batch cultivation of E. coli K1, as 
described in Appendix 6.2.1.2.  The media were sterilized by autoclaving at 121 °C for 
20 min. 
3.3.2 Bioreactor cultivations 
Cultivations were carried out at 37 °C in a stirred tank bioreactor with 2 l working volume 
(Bio-Stat® B, B. Braun Biotech, Melsungen, Germany) throughout this study. The initial 
culture conditions were the following: initial culture volume = 1.5 l (1.7 l for fed-batch 
cultivation at a constant glucose concentration of 0.1 g l-1), air flow rate = 1.5 l min-1 
(1.7 l min-1 for fed-batch cultivation at a constant glucose concentration of 0.1 g l-1), pH 
value = 7.5, stirrer speed = 800 rpm. The pH value was maintained at 7.5 by addition of 
10 % (w v-1) NaOH. Automatic control of pH value, temperature and dissolved oxygen 
were done by the digital control unit of the bioreactor. The concentrations of oxygen and 
carbon dioxide in the exhaust gas were determined by Modularsystem S710 (SICK 
MAIHAK GmbH, Reute, Germany) gas analyzer. All the on-line measurement data were 
recorded by the RISP software (real-time integrating software platform, Institute for 
Technical Chemistry, Leibniz University of Hannover). Antifoam reagent (Desmophen VP 
PU 21lK01, Bayer MaterialScience AG, Leverkusen, Germany) was added when needed. 
Culture broth volume changes by off-line sampling were manually corrected by subtracting 
the sampling volume from the culture broth volume. The construction of bioreactor system 
is shown in Appendix 6.4. The concentrations of biomass, glucose and acetate in the reactor 
were determined as described in Appendix 6.3.1. 
For fed-batch cultivations, during the fed-batch phase, the concentration of dissolved 
oxygen was kept constant at 30 % air saturation by adjusting the stirrer speed (0-
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1,200 rpm). And the feeding solution was placed on a balance to record the consumption of 
glucose over time (density of glucose feeding solution was 1.0487 g cm-3). 
3.3.3 PSA determination  
The PSA concentrations in all samples were determined using a modified thiobarbituric 
acid method described by Rode et al. (2008). The analytical procedure was described in 
Appendix 6.3.2. 
3.3.4 Process modeling 
3.3.4.1 Modeling of batch cultivation 
A simple Monod model was used (Eq. 3.1-3.4) to modeling the batch cultivation. The 
oxygen limitation during the exponential growth phase was not considered. 
	ߤ ൌ ߤ௠௔௫ ௌሺ௧ሻ௄೘ାௌሺ௧ሻ	 ሺ3.1)	
ௗ௑ሺ௧ሻ
ௗ௧ ൌ
ఓ೘ೌೣௌሺ௧ሻ
௄೘ାௌሺ௧ሻ ܺሺݐሻ	 (3.2)	
ௗௌሺ௧ሻ
ௗ௧ ൌ െ
ఓ೘ೌೣௌሺ௧ሻ
௄೘ାௌሺ௧ሻ 	
௑ሺ௧ሻ
௒೉/ೄ	 ሺ3.3)	
௑ܻ/ௌ ൌ ௱௑௱ௌ	 (3.4) 
Here,   ܺሺݐሻ – concentration of biomass at time t (g l-1); 
ܵሺݐሻ – concentration of substrate (glucose) at time t (g l-1); 
ߤ௠௔௫  – maximum specific growth rate (h-1); 
ܭ௠– Monod substrate saturation constant (g l-1); 
ߤ – specific growth rate (h-1); 
௑ܻ/ௌ – yield coefficient (g g-1). 
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3.3.4.2 Modeling of fed-batch cultivation at a constant specific growth rate 
To control the fed-batch cultivation, a process model based on the Monod model with 
limited substrate and for an ideal stirred tank bioreactor was developed using the following 
equations (Eq. 3.5-3.9): 
 ௗ௑ሺ௧ሻௗ௧ ൌ
ఓ೘ೌೣௌሺ௧ሻ
௄೘ାௌሺ௧ሻ ܺሺݐሻ െ
௏ሶಷሺ௧ሻ
௏ೃሺ௧ሻ ܺሺݐሻ (3.5) 
ௗௌሺ௧ሻ
ௗ௧ ൌ െ
ఓ೘ೌೣௌሺ௧ሻ
௄೘ାௌሺ௧ሻ 	
௑ሺ௧ሻ
௒೉/ೄ ൅
௏ሶಷሺ௧ሻ
௏ೃሺ௧ሻ ሺܵ଴ െ ܵሺݐሻሻ (3.6) 
ߤ ൌ ߤ௠௔௫ ௌሺ௧ሻ௄೘ାௌሺ௧ሻ (3.7) 
ௗ௏ೃሺ௧ሻ
ௗ௧ ൌ ሶܸிሺݐሻ (3.8) 
ሶܸிሺݐሻ ൌ ߤ௠௔௫ ௌሺ௧ሻ௄೘ାௌሺ௧ሻ 	
௑ሺ௧ሻ
௒೉/ೄ 	
ଵ
ௌబିௌሺ௧ሻ ோܸሺݐሻ (3.9) 
Where, ሶܸிሺݐሻ – feed rate at time t (l h-1); 
ோܸሺݐሻ – culture volume at time t (l); 
ܵ଴ – substrate concentration of feed solution (g l-1); 
The ordinary differential equations were solved numerically on-line by a MS-DOS program 
Neu-ork (Institute for Technical Chemistry, Leibniz University of Hannover) using the 
Runge-Kutta method of 4th order. To calculate the feed rate, a constant substrate 
concentration in the reactor was assumed (ௗௌௗ௧ ൌ 0). Thus, Eq. 3.9 was obtained from 
Eq. 3.6.  The estimated feed rate was directly used to control the feeding pump.  
3.3.4.3 Modeling of fed-batch cultivation at a constant glucose concentration 
For modeling the bioprocess, a process model was developed based on the Monod growth 
model and an ideal stirred tank bioreactor (Arndt et al., 2005). The process model consists 
of five ordinary differential equations (Eq. 3.10-3.14). 
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ௗ௑ሺ௧ሻ
ௗ௧ ൌ
ఓ೘ೌೣௌሺ௧ሻ
௄೘ାௌሺ௧ሻ ܺሺݐሻ െ
୚ሶ ూሺ୲ሻ
୚౎ሺ୲ሻ ܺሺݐሻ (3.10) 
ௗௌሺ௧ሻ
ௗ௧ ൌ െ
ఓ೘ೌೣௌሺ௧ሻ
௄೘ାௌሺ௧ሻ
௑ሺ௧ሻ
௒೉/ೄ ൅ ሺܵ଴ െ ܵሺݐሻሻ
௏ሶಷሺ௧ሻ
௏ೃሺ௧ሻ (3.11) 
ௗఓ೘ೌೣሺ௧ሻ
ௗ௧ ൌ 0 (3.12) 
ߤ ൌ ߤ௠௔௫ ௌሺ௧ሻ௄೘ାௌሺ௧ሻ (3.13) 
ௗ௏ೃሺ௧ሻ
ௗ௧ ൌ ሶܸிሺݐሻ െ ሶܸௌ (3.14) 
Here, ሶܸ௦ – sample flow rate of the FIA system (l h-1). 
3.3.5 FIA system and EKF 
A flow injection analysis (FIA) system was applied (Appendix 6.4.2) for the on-line 
measurement of glucose concentration in the culture broth. As a fast and accurate 
measurement system, FIA can measure a glucose concentration down to 0.02 g l-1 with a 
standard deviation of 0.0025 g l-1. The response time was 3 minutes which made it suitable 
for on-line measurement. A sample module (Flownamics E19, IUL Instruments GmbH, 
Königswinter, Germany) with a ceramic membrane (pore size of 0.22 µm) was used to 
continuously take cell-free medium from the reactor (sample flow rate 36 ml h-1). The 
samples (24 µl) were injected into the carrier stream and mixed with a glucose oxidase 
solution (36 µl, 500 U ml-1), which was injected by a second injector. The amount of 
oxygen used to oxidize glucose was determined by an oxygen electrode (Anasyscon, 
Hannover, Germany), from which the glucose concentration was calculated. The control of 
the FIA system and the evaluation of the measurements were carried out by a computer 
program CAFCA (computer assisted flow control and analysis) (Hitzmann et al., 1995).  
In order to minimize the glucose measurement noise and to estimate the biomass 
concentration, the maximum specific growth rate and the volume of the reaction broth, an 
extended Kalman filter (EKF) was applied (Arndt and Hitzmann, 2004) (Appendix 6.4.2). 
This program was running on a separate PC and received the glucose measurement data 
through a serial connection.  
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The Kalman filter not only provided estimated data of glucose concentration but also 
estimated data of biomass concentration, maximum specific growth rate and volume of the 
culture broth. The feeding pump rate was controlled based on these parameters and a PI 
(Proportional Integral) controller which was calculated using the following equations (3.15-
3.17): 
ሶܸிሺݐ௜ሻ ൌ ሶܸிிሺݐ௜ሻ ൅ ሶܸி஻ሺݐ௜ሻ (3.15) 
ሶܸிிሺݐ௜ሻ ൌ ߤ௠௔௫ሺݐ௜ሻ ௌሺ௧೔ሻ௄೘ାௌሺ௧೔ሻ 	
௑ሺ௧೔ሻ
	௒೉/ೄ 	
ଵ
ௌబିௌሺ௧೔ሻ ோܸሺݐ௜ሻ (3.16) 
ሶܸி஻ሺݐ௜ሻ ൌ ሶܸி஻ሺݐ௜ିଵሻ ൅ ݍ଴൫ܵ௦௘௧ െ ܵሺݐ௜ሻ൯ ൅ ݍଵሺܵ௦௘௧ െ ܵሺݐ௜ିଵሻሻ (3.17) 
Here,   ሶܸிሺݐ௜ሻ – feed rate at time ݐ௜ (l h-1); 
ሶܸிிሺݐ௜ሻ – feed rate of feedforward part of the controller at time ݐ௜ (l h-1); 
ሶܸி஻ሺݐ௜ሻ – feed rate of feedback part of the controller at time ݐ௜ (l h-1); 
ܵ௦௘௧ – substrate set point (g l-1). 
Eq. 3.16 was the feedforward part of the controller, which derived from Eq. 11 by assuming 
a constant glucose concentration in the reactor (ௗௌௗ௧ ൌ 0). Eq. 3.17 is a digital PI controller; 
the parameters were obtained by simulation to be q0= 1.4 l2 g-1 h-1 q1= -1.1 l2 g-1 h-1. If a 
negative pump rate was calculated by the controller, the pump rate would be set to zero and 
the digital PI part would be started again. 
The parameters of extended Kalman filter were obtained by simulation (data not shown) 
and presented in Table 3.1. The system construction is shown in Fig. 3.4. 
Table 3.1 Parameters of extended Kalman filter 
Parameter Name Value 
Q[1, 1] Spectral density matrix element of process noise (respect to X)  0.001 g2 l-2h-1 
Q[2, 2] Spectral density matrix element of process noise (respect to S) 0.001 g2 l-2h-1 
Q[3, 3] Spectral density matrix element of process noise (respect to µmax) 0.05   l h-3 
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Q[4, 4] Spectral density matrix element of process noise (respect to VR) 0        l2 h-1 
Q[i, j] Spectral density matrix element of process noise (i ≠ j) 0 
P[1, 1] Initial condition of estimation error covariance (respect to X) 0.1    g2 l-2 
P[2, 2] Initial condition of estimation error covariance (respect to S) 0.02  g2 l-2 
P[3, 3] Initial condition of estimation error covariance (respect to µmax ) 0.2    h-2 
P[4, 4] Initial condition of estimation error covariance (respect to VR) 0       l2 
P[i, j] Initial condition of estimation error covariance (i ≠ j) 0 
R Measurement error covariance 0.01  g2 l-2 
 
 
 
Fig.3.4 Flow chart of the control loop for keeping a constant glucose concentration in the culture 
broth. 
3.4 Results 
3.4.1 Batch cultivation of E. coli K1 
A batch cultivation with an initial glucose concentration of 18 g l-1 was performed as the 
first step for studying the PSA production in E. coli K1. An overview of the cultivation 
process is illustrated in Fig. 3.5 and Fig. 3.6. 
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Fig. 3.5 Time profile of batch cultivation with an initial glucose concentration of 18 g l-1. 
 
 
Fig. 3.6 OTR and CPR of the batch cultivation. 
As shown in Fig. 3.5, during batch cultivation cells were grown at a high specific growth 
rate of approximately 0.7 h-1. At 6.5 h, when glucose was exhausted, the highest acetate 
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level was reached (1.74 g l-1) and afterward the acetate was consumed by the cells. The 
PSA production was consistent with the biomass formation pattern and the final PSA 
concentration was 0.47 g l-1.  After 4.9 h the reactor could not provide sufficient oxygen to 
the cells, which led to the decrease of dissolved oxygen concentration to zero. From this 
time onwards, OTR (oxygen transfer rate) and CPR (carbon production rate) (Fig. 3.6) 
(calculated according to the equations in Appendix 6.4.3) were also exhibiting another 
growth pattern, indicating that anaerobic respiration as well as aerobic oxidation occurred.  
The oxygen transfer limitation, the high amount of acetate production and the low PSA 
productivity indicated that the batch cultivation was suboptimal. Therefore, fed-batch 
cultivations were exploited. Considering that the specific growth rate of 0.7 h-1 used in the 
batch cultivation was higher than the critical specific growth rate for acetate formation, a 
lower specific growth rate (0.25 h-1) was tested in the following fed-batch cultivation. 
3.4.2 Fed-batch cultivation at a controlled constant specific growth rate 
In this fed-batch cultivation experiment, an open-loop control system was utilized. The feed 
rate was calculated on-line only based on the kinetic model. The system construction is 
described in Appendix 6.4.1.  
 
Fig.3.7 Time course of fed-batch cultivation at a constant specific growth rate of 0.25 h-1. The 
arrows indicate the time when antifoam reagent was added.  
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This fed-batch cultivation was carried out at a specific growth rate set point of 0.25 h-1 in 
order to reduce acetate formation. The process profile is demonstrated in Fig. 3.7. The 
initial values of model parameters given to Neu-ork program are summarized in Table 3.2. 
Table 3.2 Initial values given to the Neu-ork program for fed-batch cultivation of E. coli K1 at 
constant growth rate of 0.25 h-1. 
Parameters 
X(t0) 
( g l-1) 
VR(t0) 
(l) 
S 
(g l-1) 
S0 
(g l-1) 
YX/S 
(g g-1) 
Km 
( g l-1) 
µset  
(h-1) 
Values 2.625 1.45 0.04 100 0.39 0.05 0.25 
 
 
Fig. 3.8 OTR, CPR and feed rate of fed-batch cultivation at a constant specific growth rate. 
As demonstrated in Fig. 3.7, after the unlimited growth in the batch phase (µ= 0.72 h-1) 
until 4.9 h, the fed-batch phase was started at a specific growth rate of µcalc= 0.24 h-1 
(calculated from off-line measurements), which was very close to the set point (µset=  
0.25 h-1). During the fed-batch phase the dissolved oxygen was maintained at 30 % air 
saturation and no acetate formation was observed (Fig. 3.7); the glucose concentration in 
the culture broth was almost 0 g l-1 all the times. The estimated biomass values were 
consistent with the off-line biomass values until 11 h (Fig. 3.7). Beyond that point, a small 
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negative deviation of the determined biomass concentrations in comparison to the estimated 
values was observed.  Perhaps the cells were not able to keep their growth on the growth 
rate set point at the end of the cultivation. The final biomass concentration was 10.6 g l-1 
and the final PSA concentration reached 0.8 g l-1. The OTR, CPR and feeding profile are 
shown in Fig. 3.8. The cultivation had to be stopped at 12 h since the culture volume (1.9 l) 
reached the maximum capacity of the reactor.  
3.4.3 Fed-batch cultivations at controlled constant glucose concentrations 
Although in the fed-batch cultivation described above no acetate was formed and a higher 
PSA concentration (0.8 g l-1) was obtained, the cells were grown under glucose limitation 
during the whole feeding phase as it is a substrate limited feeding. Therefore, fed-batch 
cultivations with a constant glucose concentration in the culture broth were performed. 
In this cultivation strategy, a feedforward/feedback closed loop control system was used. 
The feed rate was calculated based on the estimated values of the process variables. The 
construction of the cultivation system is described in Appendix 6.4.2. 
3.4.3.1 Glucose concentration set point of 0.1 g l-1 
In this fed-batch cultivation, glucose limitation was avoided by keeping a constant glucose 
concentration of 0.1 g l-1 in the culture broth. The initial glucose concentration was 3 g l-1.  
At 3.78 h the EKF software was started when the glucose concentration in the culture broth 
was 0.28 g l-1. Thus, the feeding could be started immediately after the glucose 
concentration was below the set point and a starvation period between batch and fed-batch 
phase was therefore avoided. The initial values of model parameters given to EKF software 
are listed in Table 3.3. 
Table 3.3 Initial values given to EKF software for fed-batch cultivation of E. coli K1 at a glucose 
set point of 0.1 g l-1. 
Parameters 
X(t0) 
( g l-1) 
VR(t0) 
(l) 
S(t0) 
(g l-1) 
S0 
(g l-1) 
YX/S 
(g g-1) 
Km 
( g l-1) 
 µmax(t0) 
(h-1) 
Values 0.99 1.69 0.28 100 0.30 0.01 0.40 
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Fig. 3.9 Time profile of fed-batch cultivation at a constant glucose concentration of 0.1 g l-1. 
As shown in Fig. 3.9, the cell growth followed the Monod model and the dissolved oxygen 
concentration was kept at 30 % air saturation until 7.9 h. After that time, the dissolved 
oxygen concentration started to decrease because the stirrer speed was already at the 
maximum (1,200 rpm). Therefore, the cultivation has to be stopped at 8 h. Final biomass 
concentration obtained was 9.05 g l-1 and final PSA concentration reached 0.59 g l-1.  The 
CPR and OTR (Fig. 3.10) were kept increasing throughout the fed-batch phase. 
As demonstrated in Fig. 3.11, after starting the system at 3.78 h the glucose concentration 
quickly reached the set point of 0.1 g l-1. The EKF software switched on the feed pump 
after the measured glucose concentration was below 0.1 g l-1 (Fig. 3.10 and Fig. 3.11) and 
tried to control the glucose concentration at the set point. The control system was able to 
keep the glucose concentration at 0.1 g l-1 successfully during the fed-batch phase with an 
average value of 0.104 g l-1 and a standard deviation of 0.051 g l-1. However, the off-line 
glucose concentrations were always lower than the on-line measured ones, this could be 
probably due to further consumption of glucose by the cells during sampling, although the 
samples were taken very quickly and kept on ice.  The controller maintained the maximum 
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specific growth rate around 0.4 h-1 till 6 h, after that it increased to 0.49 h-1 and then came 
back to 0.4 h-1 at the end of the cultivation. 
 
Fig.3.10 OTR, CPR and feed rate of fed-batch cultivation at a constant glucose concentration of 
0.1 g l-1. 
 
Fig.3.11 Estimated and measured glucose concentration, estimated maximum growth rate as well as 
acetate concentration during fed-batch cultivation of E. coli K1 at a glucose set point of 0.1 g l-1. 
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During the fed-batch phase the acetate concentration was around 0.2 g l-1, which was not 
negligible comparing to the cultivation at a constant specific growth rate of 0.25 h-1, 
although it was still far away from the inhibitory concentration (> 2 g l-1) (Lee, 1996). 
Evaluating the whole process, the lower biomass and PSA concentrations and the not 
negligible acetate production showed that the glucose concentration set point of 0.1 g l-1 
was not fully satisfied for PSA production. Therefore a lower glucose concentration set 
point of 0.05 g l-1 was tested. 
3.4.3.2 Glucose concentration set point of 0.05 g l-1 
In this fed-batch experiment, a lower glucose concentration set point of 0.05 g l-1 was used. 
This set point was selected in order to minimize acetate production during the fed-batch 
phase. The initial glucose concentration was 5 g l-1. The EKF control software was started 
at 4.85 h when glucose concentration in the bioreactor was 0.58 g l-1. The initial values of 
process model parameters given to EKF software are listed in Table 3.4. 
Table 3.4 Initial values given to the EKF software for fed-batch cultivation of E. coli K1 at a 
glucose set point of 0.05 g l-1. 
Parameters 
X(t0) 
( g l-1) 
VR(t0) 
(l) 
S(t0) 
(g l-1) 
S0 
(g l-1) 
YX/S 
(g g-1) 
Km 
( g l-1) 
µmax(t0) 
(h-1) 
Values 2.45 1.50 0.58 100 0.375 0.01 0.32 
 
As illustrated in Fig. 3.12, cells grew exponentially and the dissolved oxygen concentration 
was kept at 30 % air saturation. The final biomass which was obtained was 15.2 g l-1 and 
the final PSA concentration in the reactor was 1.35 g l-1. Acetate formation was not 
observed during the fed-batch phase (Fig. 3.12). After 11 h, the reactor could not keep the 
dissolved oxygen concentration at 30 % air saturation, since the stirrer speed was already at 
maximum speed (1,200 rpm). Therefore the cultivation was stopped at 11.2 h. The CPR, 
OTR as well as flow rate of the feed solution were kept increasing in the fed-batch phase 
(Fig. 3.13). 
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Fig.3.12 Time course of fed-batch cultivation at a constant glucose concentration of 0.05 g l-1. 
 
Fig.3.13 OTR, CPR and feed rate of fed-batch cultivation at a constant glucose concentration of 
0.05 g l-1. 
 
After starting the EKF software at 4.85 h, the glucose concentration quickly reached the set 
point of 0.05 g l-1 (Fig. 3.14). The software switched on the feed pump immediately after 
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the measured glucose concentration was at the first time below 0.05 g l-1 (Fig. 3.13 and Fig. 
3.14), and managed to control the glucose concentration at the set point. The average 
glucose concentration measured by FIA was 0.054 g l-1 with a standard deviation of 
0.016 g l-1 during the fed-batch phase, which proved the control being successful. 
The off-line glucose concentrations were always lower than the on-line measured ones, 
which was the same as in fed-batch cultivation at a constant glucose concentration of 
0.1 g l-1. The initial value of maximum specific growth rate given to the EKF software 
(0.32 h-1) was lower than the actual value, so that the system suddenly increased the 
estimated growth rate to 0.38 h-1. Afterwards the growth rate was decreasing very slowly 
throughout the feeding phase with an average value of 0.35 h-1 (Fig. 3.14).  
 
Fig.3.14 On-line, off-line measured and EKF estimated glucose concentrations as well as estimated 
maximum growth rate during the fed-batch at a glucose set point of 0.05 g l-1. 
 
An unusual high glucose concentration was obtained at 10.2 h (Fig. 3.14), which was most 
likely caused by an air bubble in the FIA system. As a consequence, the feeding rate was 
drastically decreased by the control system. The whole process was suddenly disturbed, as 
can be seen from all process variables. This effect was simply due to temporary problems 
in the analytical system. As soon as the analysis system stabilized again, the cultivation 
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process itself became stable immediately, suggesting that the whole control system was 
fault-tolerant in total.  
Assessing the whole cultivation, at lower glucose concentration set point (0.05 g l-1) the 
biomass concentration in the reactor reached 15.23 g l-1 and PSA concentration was 
1.35 g l-1 after feeding for 6 h proved that it was more efficient than the higher glucose 
concentration set point (0.1 g l-1). 
3.4.4 Comparison of biomass and PSA productivity under different cultivation 
strategies 
The biomass and PSA productivity under three different cultivation strategies are shown in 
Table 3.5 and 3.6. Compared to biomass and PSA yield on glucose (YX/S and YP/S), fed-
batch cultivations were higher than that of the batch cultivation. Since they avoided 
overflow metabolism (i.e. formation of acetate) and oxygen transfer limitation, the 
efficiency of the cultivation was significantly improved. The highest biomass yield 
obtained was 0.49 g g-1 with the highest PSA yield of 0.043 g g-1 in the fed-batch 
cultivation at a constant glucose concentration of 0.05 g l-1. 
Table 3.5 Comparison of biomass and PSA production in batch and fed-batch cultivations. 
 
µesti (h-1) µcalc (h-1) 
Final Biomass 
concentration  
(g l-1) 
Final PSA 
concentration  
(g l-1) 
Time-space-yield 
of PSA (g l-1 h-1) 
Batch  0.70 6.15 0.47 0.068 
Fed-batch at a 
constant µ of 
0.25 h-1 
µesti= 0.25 0.24 10.59 0.80 0.067 
Fed-batch at a 
constant S of 
0.1 g l-1 
μmax= 0.43 0.46 9.05 0.59 0.074 
Fed-batch at a 
constant S of 
0.05 g l-1 
μmax= 0.35 0.32 15.23 1.35 0.122 
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Table 3.6 Comparison of biomass and PSA yield on glucose in batch and fed-batch cultivations. 
 YX/S (g g-1) YP/S (g g-1) YA/S (g g-1) PSA carbon yield 
(CPSA/Cglucose) (%) 
Batch 0.35 0.026 0.094 2.79 
Fed-batch at a 
constant µ of 0.25 h-1 0.38 0.035 0 3.71 
Fed-batch at a 
constant S of 0.1 g l-1 
0.46 0.030 0.011 3.22 
Fed-batch at a 
constant S of 0.05 g l-1 
0.49 0.043 0 4.63 
3.5 Discussion 
3.5.1 Acetate formation under different cultivation strategies 
A common factor limiting the efficiency of E. coli cultivations is the formation of acetate. 
Studies in continuous cultures (Brown et al., 1985; Meyer et al., 1984) have revealed that 
the formation of acetate occurred when specific growth rate was above 0.35 h-1 in a defined 
medium or 0.2 h-1 in a complex medium.  
In our previous study (Rode et al., 2008), we have cultivated E. coli K1 at a controlled 
specific growth rate of 0.35 h-1. We found that the acetate production was significantly 
decreased (< 0.5 g l-1) compared to the batch cultivation (> 1.6 g l-1), but still could not be 
eliminated totally. In this study, we performed the fed-batch cultivation at a constant 
specific growth rate of 0.25 h-1 and could not detect any acetate accumulation during the 
feeding phase. This indicated that the growth rate of 0.35 h-1 was higher than the critical 
growth rate of acetate formation. While for fed-batch cultivations with a constant glucose 
concentration, at a growth rate of 0.32 h-1 there was no acetate produced during the fed-
batch phase, even at a growth rate of 0.46 h-1 only about 0.2 g l-1 acetate was produced. 
Therefore, we assumed the threshold for acetate production varied with different cultivation 
strategies. The fed-batch cultivation at a constant glucose concentration gave better results 
than the fed-batch cultivation at a constant specific growth rate, since it provided better 
conditions for cell growth. 
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3.5.2 Comparison of biomass yield under different cultivation strategies 
No acetate was observed in the fed-batch cultivation at a constant growth rate of 0.25 h-1, 
thus a higher biomass yield was expected. However, since the efficient glucose 
concentration during the fed-batch phase was nearly zero, the glucose limitation might have 
forced the cells to use more energy for cell maintenance rather than for cell growth. This 
might be the main reason for the slightly different biomass yield on glucose between this 
cultivation (0.38 g g-1) and the batch cultivation (0.35 g g-1) even the PSA yield on glucose 
was slightly increased in the fed-batch process. This explanation was supported by the fact 
that the biomass yield on glucose increased in fed-batch cultivation with a constant glucose 
concentration of 0.1 g l-1 and 0.05 g l-1 (0.46 g g-1, 0.49 g g-1 respectively). For fed-batch 
cultivation at a glucose concentration set point of 0.1 g l-1, the biomass yield was a little bit 
lower than fed-batch cultivation at a glucose concentration set point of 0.05 g l-1 that might 
be at higher glucose set point the cells were growing too fast and around 0.2 g l-1 acetate 
was produced throughout the fed-batch phase while at lower glucose concentration set 
point (0.05 g l-1) no acetate formation was detected. Therefore the highest biomass yield 
was obtained in fed-batch cultivation at a glucose concentration set point of 0.05 g l-1. 
3.5.3 Comparison of PSA yield under different cultivation strategies 
As shown in Table 3.5 and Table 3.6, fed-batch cultivation strategies have greatly increased 
the PSA yield on glucose (YP/S). The final PSA concentration obtained from the fed-batch 
cultivation at a constant specific growth rate of 0.25 h-1 was nearly 2 times higher and at a 
constant glucose concentration of 0.05 g l-1 was nearly 3 times higher compared to that of 
the batch cultivation. While for the fed-batch cultivation at a constant glucose concentration 
of 0.1 g l-1 the final PSA concentration only increased 26 % compare to the batch 
cultivation. Comparing the two feeding strategies, the time-space-yield of fed-batch at a 
constant glucose concentration of 0.05 g l-1 was 82 % higher than the fed-batch cultivation 
at a constant specific growth rate of 0.25 h-1. It is clear that maintain a very low glucose 
concentration in the reactor was more efficient for PSA production. Supposing we could 
extend the cultivation time by blending air with pure oxygen, a final PSA concentration up 
to 2 g l-1 should be possible. 
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3.5.4 Effect of specific growth rate on PSA production  
It should be pointed out that the PSA yield on glucose (YP/S) was correlated to the specific 
growth rate of the cells. The relationship is plotted in Fig. 3.15. In the first place, the PSA 
yield on glucose increased according to the increase in the specific growth rate up to its 
maximum and then decreased. At extremely high specific growth rate (0.7 h-1), which was 
obtained from the batch cultivation, the PSA yield on glucose was very low (0.026 g g-1). 
However, at lower specific growth rate (0.24 h-1) obtained from the fed-batch cultivation at 
a constant specific growth rate, the PSA yield was also relatively low (0.035 g g-1). For the 
specific growth rate of 0.46 h-1, the PSA yield on glucose was in between that of 0.7 h-1 and 
0.24 h-1. The maximal PSA yield on glucose (0.043 g g-1) was obtained at a specific growth 
rate of 0.32 h-1 in the fed-batch cultivation at a constant glucose concentration of 0.05 g l-1. 
These cultivation conditions were therefore considered to be the optimal conditions for 
PSA production in E. coli K1. 
 
Fig. 3.15 Correlation of PSA yield to glucose at different specific growth rates. 
3.6 Summary and conclusion 
In this work, different cultivation strategies were used for the optimization of PSA 
production in E. coli K1. The preliminary study started with a batch cultivation and an 
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initial glucose concentration of 18 g l-1. The results demonstrated that in the batch 
cultivation the cells were growing at an extremely high specific growth rate of 0.7 h-1 and 
giving a biomass yield on glucose of 0.35 g g-1, PSA yield on glucose of 0.026 g g-1 with 
high amount of acetate up to 1.74 g l-1. 
In order to reduce acetate production, fed-batch cultivations were introduced. An 
exponential feeding strategy with a controlled constant specific growth rate of 0.25 h-1 was 
used. The results revealed that in the fed-batch cultivation acetate formation during the fed-
batch phase was prevented. Biomass yield and PSA yield on glucose were increased to 
0.38 g g-1 and 0.035 g g-1, separately. 
To overcome the glucose limitation in exponential feeding, a feedback/feedforward control 
system was used to keep a constant glucose concentration in the bioreactor. The system 
consisted of a FIA system for the on-line glucose measurement and an extended Kalman 
filter for the estimation and control of the bioprocess. Fed-batch cultivations were carried 
out at two different glucose set points 0.1 g l-1 and 0.05 g l-1. At the glucose set point of 
0.1 g l-1, the biomass yield on glucose reached 0.46 g g-1 with PSA yield on glucose of 
0.03 g g-1. The specific growth rate was around 0.46 h-1 and non-ignorable 0.2 g l-1 acetate 
was produced throughout the fed-batch phase. While at the glucose set point of 0.05 g l-1, 
the yield of biomass on glucose increased incredibly to 0.49 g g-1 and the PSA yield on 
glucose increased to 0.043 g g-1 with no detectable acetate formation during the fed-batch 
phase. 
The cultivation experiments of E. coli K 1 with different strategies revealed that the PSA 
production was correlated to the specific growth rate of the cells. Fed-batch cultivation with 
a constant glucose concentration was the best cultivation condition for PSA production. 
The optimal specific growth rate for PSA production was 0.32 h-1. 
3.7 Outlook and future work 
Future work could include scaling up of the fed-batch cultivation to 10 l and 30 l, blending 
air with pure oxygen to overcome the oxygen supply limitation, further optimization of 
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cultivation medium for high cell density cultivation and developing better FIA system for 
the on-line measuring of glucose concentration at even lower set points such as 0.01 g l-1. 
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4. Bench-scale production and purification of FGF-2 
4.1 Introduction 
4.1.1 FGF family and FGF-2 
Fibroblast growth factors (FGFs) are a large family of cytokines which are widely 
distributed among various organisms. There are 22 members in the human FGF family and 
their structures are highly correlated (Ornitz and Itoh, 2001).  FGFs have great affinity to 
heparin and they play an important role in cell proliferation, differentiation, survival and 
apoptosis (Böttcher and Niehrs, 2005). 
 
Fig. 4.1 Primary sequence of human FGF-2. 
  1                                                                 10
Met Ala Ala Gly Ser Ile Thr Thr Leu Pro Ala Leu Pro Glu Asp Gly Gly
                20                                                                          30
Ser Gly Ala Phe Pro Pro Gly His Phe Lys Asp Pro Lys Arg Leu Tyr Cys
                                        40                                                                         50
Lys Asn Gly Gly Phe Phe Leu Arg Ile His Pro Asp Gly Arg Val Asp Gly
                                                             60
Val Arg Glu Lys Ser Asp Pro His Ile Lys Leu Gln Leu Gln Ala Glu Glu
        70                                                                      80
Arg Gly Val Val Ser Ile Lys Gly Val Cys Ala Asn Arg Tyr Leu Ala Met
                                 90                                                                       100
Lys Glu Asp Gly Arg Leu Leu Ala Ser Lys Cys Val Thr Asp Glu Cys Phe
                                                        110
Phe Phe Glu Arg Leu Glu Ser Asn Asn Tyr Asn Thr Tyr Arg Ser Arg Lys
120                                                                     130
Tyr Thr Ser Trp Tyr Val Ala Leu Lys Arg Thr Gly Gln Tyr Lys Leu Gly
                       140                                                                      150
Ser Lys Thr Gly Pro Gly Gln Lys Ala Ile Leu Phe Leu Pro Met Ser Ala
       155
Lys Ser
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FGF-2 was first isolated by Denis Gospodarowicz (1974) from pituitary and brain as a 
basic protein (pI of 9.6). Therefore it was named basic fibroblast growth factor (bFGF, 
FGF-2) and it was also the first member of the FGF family. 
The FGF-2 as described in this work is a recombinant, human, non-glycosylated protein, 
consisting of 155 amino acids. The primary sequence of human FGF-2 is presented in 
Fig. 4.1. 
4.1.2 Physicochemical properties 
X-ray diffraction analysis revealed that FGF-2 is composed of 12 β strands connected by β 
turns (Eriksson et al., 1993; Eriksson et al., 1991; Zhang et al., 1991; Zhu et al., 1991).  The 
Three-dimensional structure of FGF-2 is shown in Fig. 4.2.  
 
Fig. 4.2 Three-dimensional structure of FGF-2. A ribbon diagram of FGF-2 is shown and strands 
are labeled as β1-β12.  The heparin-binding region (pink colored) includes residues in the loop 
between β strands 1 and 2 and in β strands 10 and 11.  Residues contact with the FGFRs (fibroblast 
growth factor receptors) are shown in green (the region contacting Ig-domain 2 of the receptor), 
blue (contacting Ig-domain 3) and red (contacting the alternatively spliced region of Ig-domain 3). 
Amino acid residues that contact the linker region are shown in gray (Plotnikov et al., 2000). This 
figure has been adapted from Ornitz and Itoh (2001). 
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FGF-2 has two exposed cysteines (78 and 96) and two buried cysteines (34 and 101). The 
two exposed -SH groups can form disulfide-link when contacted with air, which makes the 
protein unstable (Thompson and Fiddes, 1991). Replacing the two cysteine residues (78 
and 96) by serine residues can significantly improve its stability and bioactivity (Arakawa 
et al., 1989; Seno et al., 1988). FGF-2 only has a single tryptophan residue. The 
fluorescence from this tryptophan residue is completely suppressed in the properly folded 
protein and increases when the protein is unfolded (Shahrokh et al., 1994). Therefore, in the 
native protein the fluorescence emission spectrum is dominated by tyrosine fluorescence.  
FGF-2 has a strong affinity to glycosaminoglycans (GAGs) such as heparin, heparin sulfate 
and heparan sulfate. Heparin can also protect FGF-2 from digestion by trypsin and 
inactivation by heat and acid (Gospodarowicz and Cheng, 1986). This feature was also 
utilized for the purification of FGF-2 (Garke et al., 2000; Iwane et al., 1987; Seeger and 
Rinas, 1996; Shing, 1988; Squires et al., 1988).  
4.1.3 Biologic activity 
FGF-2 is a potent mediator of cell proliferation and differentiation both in vitro and in vivo 
(Burgess and Maciag, 1989). It can stimulate the division of a variety of cells such as 
smooth muscle cells, fibroblasts, myoblasts and osteoblasts (Schweigerer, 1988). 
Moreover, FGF-2 can accelerate wound healing (Albertson et al., 1993; Tsuboi et al., 
1992), tissue regeneration (Bikfalvi et al., 1997) and involves in the development or 
function of the nervous system (Baird, 1994; Logan et al., 1991), the lung (Han et al., 
1992b; Sannes et al., 1992), the reproductive system (Murono et al., 1992), the skin 
(Halaban et al., 1992), the eye (McAvoy et al., 1991; Park and Hollenberg, 1993), the 
muscle and the skeleton (Fallon et al., 1994; Templeton and Hauschka, 1992) and the 
digestive system (Iida et al., 1994; Szabo et al., 1994). 
4.1.4 Applications 
4.1.4.1 Cell culture  
FGF-2 was widely used in the cultivation of various cells, such as mesenchymal stem cells, 
embryonic stem cells (ESC), neural cells and endothelial cells. Since FGF-2 can maintain 
the cells in an undifferentiated state, it has been extensively used in human ESC culture 
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(Amit et al., 2000; Liu et al., 2006). In recent years, its application in tissue engineering has 
also been investigated (King et al., 2009; Macdonald et al., 2010; Marra et al., 2008; 
Nakamura et al., 2009; Pei et al., 2002). 
4.1.4.2 Wound healing and tissue regeneration 
Diabetics often have weakened wound healing, however, treating with FGF-2 could 
accelerate healing (Fiddes et al., 1991). FGF-2 can stimulates the healing of experimental 
duodenal ulcers in rats (Szabo et al., 1994) as well as diabetic foot ulcers (Bennett et al., 
2003). It can also be used for the  therapy of herpetic stromal keratitis (Kim et al., 2006) and 
reformation of periodontal tissues (Murakami et al., 1999). In addition, FGF-2 could assist 
the regeneration of alveolar bone in the treatment of periodontitis (Kitamura et al., 2008). 
4.1.4.3 Other therapeutic potential 
Chemoresistance is a main problem in cancer treatment. This resistance was regulated by 
acidic and basic fibroblast growth factors (Roidl et al., 2009; Song et al., 2000). Low level 
of suramin (inhibitor of FGFs) could reduce the FGF-induced resistance and increase the 
efficiency of chemotherapy (Song et al., 2001; Song et al., 2004; Xin et al., 2005; Zhang et 
al., 2001). Wang and Becker (1997) also reported that suppression of FGF-2 signaling can 
restrain tumor growth by inhibiting vascularization. FGF-2 has also been applied in the 
treatment of peripheral circulation and mood disorders (Beenken and Mohammadi, 2009). 
4.1.5 Production and purification 
Several purification processes have been established for the production of recombinant 
FGF-2 from E. coli in the past 20 years. They can be mainly classified into three types: (1) 
single step purification by heparin affinity chromatography (Ke et al., 1992; Squires et al., 
1988). (2) combination of cation exchange column chromatography and heparin affinity 
chromatography (Iwane et al., 1987; Knoerzer et al., 1989; Patry et al., 1994; Seeger and 
Rinas, 1996; Wang et al., 2006). (3) combination of continuous bed or expanded bed 
chromatography and heparin affinity chromatography (Garke et al., 2000; Garke et al., 
1999).  However, these already existed processes have multiple disadvantages. During the 
first process, part of FGF-2 is lost which resulting in low protein recovery. In the second 
process, the used of cation exchange column chromatography has significantly improved 
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the protein recovery rate, but the long process time and subsequent dialysis step reduce the 
efficiency of the whole process. Although the use of continuous bed or expanded bed 
chromatography in the third process can treat cell lysate directly without separation, the 
binding capacity is lower or just comparable to that of cation exchange column 
chromatography. In addition, some authors have also produced FGF-2 from a fusion 
protein (Gasparian et al., 2009; Kroiher et al., 1995; Lappi et al., 1994; Lemaître et al., 
1995; Sheng et al., 2003). However, extra cleavage step is needed to obtain FGF-2, which 
could lower down the protein yield. For these reasons, the methods described above are not 
cost-effective for large scale production of FGF-2.  
4.1.6 Membrane adsorber technology 
Membrane adsorbers have been extensively used for protein purification (Ghosh, 2002; 
Roper and Lightfoot, 1995; Thoemmes and Kula, 1995; Zeng and Ruckenstein, 1999). 
They consist of microporous or macroporous membranes which incorporate functional 
ligands in the inner pore surface as adsorbents. The transfer of fluid through the membrane 
is dominated by convective flow, while pore diffusion is prevented. That results in lower 
back pressure, higher flow rate, shorter resident time and higher productivity as compared 
to conventional chromatographic packed columns (Krause et al., 1991; Kubota et al., 1996). 
In this study, different membrane adsorbers were used for the efficient and cost-effective 
purification of FGF-2. 
4.2 Bacterial strain 
E. coli strain BL21(DE3) (Novagen, Darmstadt, Germany) transformed with the plasmid 
pET29c(+)-hFGF-2 which contains a cDNA encoding for human basic fibroblast growth 
factor (155 AA) was used in this study. The plasmid was constructed by the group of PD 
Dr. Ursula Rinas at HZI (Helmholtz Centre for Infection Research,  Inhoffen Str. 7, 38124 
Braunschweig) (Hoffmann et al., 2004), the FGF-2 coding sequence was previously 
described by Knoerzer et al. (1989). The strain was stored as a 50 % (v v-1) glycerol stock at 
- 80 °C. 
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4.3 Cultivation and purification 
4.3.1 Preculture and medium 
A LB medium (see Appendix 6.2.2.1) supplemented with 30 µg ml-1 kanamycin was used 
as preculture medium. The preculture was incubated on a rotary shaker at 30 °C, 120 rpm 
for 12-14 h and then directly used to inoculate the bioreactor. A synthetic medium was 
prepared according to Seeger et al. (1995) and used for the fed-batch cultivation of E. coli 
BL21, as described in Appendix 6.2.2.2. The media were sterilized by autoclaving at 
121 °C for 20 min except thiamine·HCl and kanamycin solution which were sterilized by 
filtration. 
4.3.2 Bioreactor cultivation 
Cultivations were carried out at 30 °C in a 2 l stirred tank bioreactor (Bio-Stat® B; B. Braun 
Biotech, Melsungen, Germany). The initial culture conditions were the following: initial 
culture volume = 1.5 l, air flow rate = 1.5 l min-1, pH value = 6.9, stirrer speed = 800 rpm. 
The pH value was maintained at 6.9 by adding 25 % (w w-1) ammonia solution. Automatic 
control of pH value, temperature and dissolved oxygen were done by the digital control unit 
of the bioreactor. The concentrations of oxygen and carbon dioxide in the exhaust gas were 
determined by Modularsystem S710 gas analyzer (SICK MAIHAK GmbH, Reute, 
Germany). All the on-line measurement data were recorded by the RISP software (real-time 
integrating software platform, Institute for Technical Chemistry, Leibniz University of 
Hannover). Antifoam reagent (Desmophen VP PU 21lK01, Bayer MaterialScience AG, 
Leverkusen, Germany) was added when needed. The diagram of the bioreactor system is 
shown in Appendix 6.4.1. 
Off-line samples were taken approximately every hour and optical density was measured at 
600 nm (OD600) on a spectrophotometer (Uvikon 922;  Kontron Instruments, Basel, 
Switzerland). The concentrations of biomass, glucose and acetate were determined as 
described in Appendix 6.3.1.   
When the batch phase was finished, as indicated by a sudden increase in the dissolved 
oxygen concentration, the fed-batch phase was started. During the fed-batch phase, the 
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concentration of dissolved oxygen was kept constant at 30 % air saturation by adjusting the 
stirrer speed (0-1,200 rpm). A process model for keeping constant growth rate was used to 
control the feed flow rate. The feeding solution was placed on a balance to record the 
consumption of glucose over time (density of glucose feeding solution was 1.044 g cm-3). 
Culture broth volume changes by off-line sampling were manually corrected by subtracting 
the sampling volume from the culture broth volume. The protein expression was induced 
by adding 1 mM IPTG when OD reached 15 as indicated in Fig. 4.3 and Fig. 4.5.  
4.3.3 Bioprocess model 
To control the fed-batch cultivation, a process model was developed based on the Monod 
model with limited substrate and an ideal stirred tank bioreactor (see section 3.3.4.2). 
4.3.4 Fed-batch cultivations of E. coli BL21at different specific growth rates 
Fed-batch cultivations were carried out at two different specific growth rates (0.35 h-1, 
0.15 h-1) in order to study the effect of preinduction specific growth rate on recombinant 
product formation. The cells firstly grew at a constant specific growth rate-µset in the fed-
batch phase until OD reached 15 and then the protein production was induced by adding 
1 mM IPTG to the reactor. 
4.3.4.1 Fed-batch cultivation of E. coli BL21 at µset = 0.35 h-1 
An initial glucose concentration of 4 g l-1 was used in the fed-batch cultivation and the 
overview of the production process is presented in Fig. 4.3. The initial values of model 
parameters given to the Neu-ork program are summarized in Table 4.1. 
Table 4.1 Initial values given to the Neu-ork program for fed-batch cultivation of E. coli BL21 at a 
constant growth rate of 0.35 h-1. 
Parameters 
X(t0) 
(g l-1) 
VR(t0) 
(l) 
S 
(g l-1) 
S0 
(g l-1) 
YX/S 
(g g-1) 
Km 
( g l-1) 
µset  
(h-1) 
Values 1.75 1.45 0.04 100 0.41 0.05 0.35 
 
After unlimited growth in the batch phase (µ = 0.39 h-1), as indicated by a sharp increase in 
dissolved oxygen concentration, the fed-batch phase was started at a specific growth rate of 
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µcalc = 0.34 h-1 (µset = 0.35 h-1) as shown in Fig. 4.3. The FGF-2 production was induced by 
adding 1 mM IPTG to the reactor at 9.2 h when OD reached 15 (Fig. 4.3). The OTR and 
CPR was calculated according to the equations in Appendix 6.4.3 and shown in Fig. 4.4.  
 
Fig. 4.3 IPTG induced FGF-2 production during Fed-batch cultivation of E. coli at a constant 
growth rate of µset = 0.35 h-1. The disturbance in dissolved oxygen concentration at about 11.4 h was 
caused by the adding antifoam reagent. 
E. coli BL21 strain was known to produce little acetate even at high growth rates (Shiloach 
et al., 1996). During the fed-batch phase the acetate concentrations were less than 0.15 g l-1 
(Fig. 4.3) which were far away from the inhibitory concentration (> 2 g l-1) (Lee, 1996). A 
high concentration of acetate (1.34 g l-1) at the beginning of the cultivation came from the 
preculture (Fig. 4.3). 
During the fed-batch phase the dissolved oxygen concentration was maintained at 30 % air 
saturation and glucose concentrations in the bioreactor were always near 0 g l-1 (Fig. 4.3). 
The estimated biomass values were agreed with off-line biomass values until 11 h and after 
that a negative deviation was observed (Fig. 4.3). OTR, CPR kept increasing until 10.8 h 
and feed flow rate kept increasing throughout the fed-batch phase (Fig. 4.4). Final biomass 
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concentration reached 10.8 g l-1 and final FGF-2 concentration in the reactor was 0.489 g l-1 
(estimated as described in Appendix 6.3.3.2). 
 
Fig. 4.4 OTR, CPR and feed rate during fed-batch cultivation of E. coli BL21 at a constant specific 
growth rate of µset = 0.35 h-1. 
4.3.4.2 Fed-batch cultivation of E. coli BL21 at µset = 0.15 h-1 
This fed-batch cultivation was started with an initial glucose concentration of 3.5 g l-1. The 
process profile is presented in Fig. 4.5. The initial values of model parameters given to the 
Neu-ork program are listed in Table 4.2. 
Table 4.2 Initial values given to the Neu-ork program for fed-batch cultivation of E. coli BL21 at 
constant growth rate of 0.15 h-1. 
Parameters 
X(t0) 
( g l-1) 
VR(t0) 
(l) 
S 
(g l-1) 
S0 
(g l-1) 
YX/S 
(g g-1) 
Km 
( g l-1) 
µset  
(h-1) 
Values 1.48 1.45 0.04 100 0.40 0.05 0.15 
As illustrated in Fig. 4.5, after unlimited growth in the batch phase (µ = 0.44 h-1), the fed-
batch phase was started at a specific growth rate of µcalc = 0.13 h-1 (µset = 0.15 h-1). The 
FGF-2 production was induced by adding 1 mM IPTG to the reactor at 15.2 h when OD 
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reached 15 (Fig. 4.5). The OTR and CPR during the fed-batch cultivation are shown in 
Fig. 4.6.  
 
Fig. 4.5 IPTG induced FGF-2 production during Fed-batch cultivation of E. coli at a constant 
growth rate of µset = 0.15 h-1. 
During the fed-batch phase the dissolved oxygen concentration was maintained at 30 % air 
saturation and glucose concentrations in the bioreactor were always about 0 g l-1 (Fig. 4.5). 
The estimated biomass values were agreed with off-line biomass values until 18 h and after 
that a small negative deviation was observed (Fig. 4.5). Acetate concentrations in the fed-
batch phase were always 0 g l-1 (Fig. 4.5). OTR, CPR and feed rate kept increasing in the 
fed-batch phase (Fig. 4.6). The final biomass concentration reached 8.25 g l-1 and final 
FGF-2 concentration in the reactor was 0.257 g l-1 (estimated as described in Appendix 
6.3.3.2). 
In the first 3.5 h of the fed-batch phase, the feed flow rate fluctuated between the minimum 
feed rate and 0 l h-1(Fig. 4.6), that might because the initial biomass concentration of the 
fed-batch phase was too low, therefore the calculated feeding pump rate was sometimes 
lower than the minimum pump rate and the pump was switching between off and the 
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minimum pump rate. But the increase in biomass concentration raised the demand for 
glucose so that the feed flow rate kept increased after 9 h.  
 
Fig. 4.6 OTR, CPR and feed rate during fed-batch cultivation of E. coli BL21at a constant specific 
growth rate of µset = 0.15 h-1. 
4.3.4.3 Comparison of biomass and FGF-2 production at different growth rates 
At the higher specific growth rate (0.35 h-1), the final biomass and FGF-2 concentrations 
were both higher than that at lower specific growth rate (0.15 h-1) (Table 4.3). However, 
more soluble FGF-2 fractions (about 13 %) were obtained at the lower specific growth rate 
(0.15 h-1) (Table 4.3). This indicated lower specific growth rate might be better for the 
proper folding of FGF-2. 
Table 4.3 Comparison of biomass and protein production at different specific growth rates 
µset (h-1) Final biomass (g l-1) 
Final FGF-2 concentrationa 
(mg g-1 dry cell) 
Soluble FGF-2 to total 
FGF-2a (%) 
0.35 10.8 42 46 
0.15 8.25 31 59 
a estimated by gel densitometry. 
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As shown in Table 4.4, the biomass yields were nearly the same at both growth rates before 
induction (0.48 g g-1 and 0.47 g g-1 for µset = 0.35 h-1 and µset = 0.15 h-1, respectively) but 
both decreased drastically after induction (0.28 g g-1, 0.35 g g-1 respectively), which 
demonstrated that protein expression has significantly affected the cell growth. However, 
the biomass yield on glucose was higher at µset = 0.15 h-1 (0.42 g g-1) indicated that the cells 
using glucose more efficiently.  
This explanation was supported by the respiratory quotient (RQ) value (see Appendix 
6.4.3), at µset = 0.35 h-1 the RQ value was 0.99, very close to the theoretical RQ value of 
glucose (RQ = 1). However, at µset = 0.15 h-1 the RQ value was only 0.89 which indicated 
the metabolic direction has changed at lower growth rate. The cells utilized oxygen but 
produced less carbon dioxide, in other words, they converted more glucose to biomass 
rather than carbon dioxide via pure metabolic oxidation. 
Table 4.4 Comparison of biomass yield on glucose at different specific growth rates 
µset (h-1) YX/S ( g g-1) 
YX/S ( g g-1) before 
induction 
YX/S ( g g-1) After 
induction till end 
0.35 0.33 0.48 0.28 
0.15 0.42 0.47 0.35 
 
Table 4.5 Comparison of protein yield on glucose and biomass at different specific growth rates 
µset (h-1) 
Yield(total 
protein/glucose ) 
(g g-1) 
Yield 
(Soluble protein/ 
glucose) (g g-1) 
Yield 
(Soluble protein/ 
biomass) (g g-1) 
Time-space yield of 
soluble proteina     
(g l-1 h-1) 
 
0.35 0.014 0.0065 0.019 0.056 
0.15 0.012 0.0070 0.018 0.038 
a Calculated only for the production phase (after induction till end of the cultivation). 
For protein yield, the yield of soluble protein on biomass was nearly the same at two 
different growth rates (Table 4.5). While at µset = 0.15 h-1 the yield of soluble protein on 
glucose increased a little bit comparing to that at µset = 0.35 h-1 (Table 4.5).  
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But for the time-space yield of soluble protein, at µset = 0.35 h-1 was 47.3 % higher than that 
at µset = 0.15 h-1. Since the protein production rate was very high at µset = 0.35 h-1, more 
soluble protein were produced in a given period of 4 h, although the soluble protein 
fractions were less than that of µset = 0.15 h-1. Besides, using higher growth rate not only 
can save time, but also save the cost for maintaining the cultivation system and labor work. 
Therefore, the specific growth rate of 0.35 h-1 was selected to be the better condition for 
FGF-2 production.    
4.3.4.4 Effect of specific growth rate on FGF-2 production 
Specific growth rate can affect recombinant product yield, although it was quite case 
specific. For example, Riesenberg et al. (1990) reported that interferon alpha 1 productivity 
was higher when the specific growth rate was relatively low (0.15 h-1) in fed-batch 
cutivations. While Curless et al. (1990) found that E. coli produced recombinant alpha 
consensus interferon more efficiently when the preinduction specific growth rate increased 
from 0.025 h-1 to 0.2 h-1. However, Hellmuth et al. (1994) and Park et al. (1990) considered 
there should be an optimal cell growth rate, at which the maximum protein productivity 
could be obtained. Moreover, Zabriskie et al. (1987) found that there was no relationship 
between preinduction cell growth rate and recombinant malaria antigen productivity.  
In this study, FGF-2 expression level was increased with the increase in specific growth 
rate (31 and 42 mg g-1 dry cell, for µset= 0.15 and 0.35 h-1, respectively). Sandén et al. 
(2003) investigated the limiting factors of recombinant β-galactosidase production in 
E. coli at different specific growth rates. They predicted that at higher specific growth rates 
(e.g. 0.5 h-1) the protein production was transcription limited while at lower specific growth 
rates (e.g. 0.1 h-1) it was substrate limited. Therefore, I considered there was an optimal 
specific growth rate for FGF-2 production. As it was well known that at even higher 
specific growth rates (e.g. 0.5 h-1), loss of plasmids and degradation of ribosome would 
reduce the protein synthetic capacity (Dong et al., 1995b), while at even lower specific 
growth rates (e.g. 0.05 h-1), cell starvation and endogenous metabolism would also lower 
the productivity of recombinant protein. However, further experiments on the ribosome 
content, plasmid stability at different growth rates are needed to prove this hypothesis.   
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4.3.4.5 Comparison of cell growth rates after induction 
As shown in Fig. 4.3 and 4.5, the estimated biomass concentrations were consistent with 
off-line biomass concentrations before induction, which demonstrated the open-loop 
control system was effective in controlling the specific growth rates at the set values. But 
after induction the off-line biomass concentrations started to deviate from the estimated 
biomass concentrations. This was due to the cells were not able to keep their growth on the 
growth rate set point since over-expression of FGF-2 imposed metabolic burden on the 
cells. As shown in Table 4.6, the specific growth rates after induction were drastically 
decreased at both growth rate set points, therefore the cells were harvested at 4 h after 
induction. 
Table 4.6 Specific growth rates after induction at different growth rates 
Cultivations 
Specific growth rate after induction (h-1) 
2 h after induction 3 h after induction 4 h after induction
µset = 0.35 h-1 0.319 0.175 0.156 
µset = 0.15 h-1 0.148 0.097 0.057 
 
4.3.5 Downstreaming and purification 
Since soluble FGF-2 fraction was about 50 % (46 % and 59 %, respectively, as estimated 
by gel densitometry) of the total protein expressed, the downstreaming process was 
designed to isolate FGF-2 from the soluble protein fractions. Since the downstreaming 
processes for the two cultivations were the same, only the downstreaming processes of the 
cultivation with a constant specific growth rate of 0.35 h-1 are discussed here. 
Part of the optimization of the downstreaming and purification process was done by my 
Diplom student Yangxi Zhao (2008). The purification processes described here is based on 
the optimized conditions. The flow chart of whole downstreaming and purification process 
is presented in Fig 4.7. It is clear that by using membrane adsorbers, we can produce 
bioactive FGF-2 in just 12 steps. The detailed downstreaming and purification processes 
are described in the following sections.  
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Fig. 4.7 Flow chart of the whole downstreaming and purification process for FGF-2 production. 
4.3.5.1 Cell harvest 
After the cultivation, 1.9 l of culture broth was distributed into 500 ml centrifuge tubes.  
Cells were harvested by centrifugation for 20 min at 4,000 rpm (3,345 × g) and 4 °C 
(Megafuge® 1.0 RS,  Heraeus, Hanau, Germany). About 80 g cell pellets were collected and 
stored at -20 °C until used.  
4.3.5.2 Cell disruption and separation 
After thawing, 20 g of the cell pellets were resuspended in lysis buffer (25 mM phosphate 
buffer pH 7.5, 100 mM NaCl, 0.25 g l-1 MgCl2·7H2O, 1 U ml-1 benzonase with 3 mM DTT 
and 1 mM EDTA) to a final volume of 100 ml.  Cell suspension was fed into a high 
pressure homogenizer (M-110L; Microfluidics, Newton, USA). Cells were disrupted by 6 
discrete passages through the interaction chamber at 620 bar (9,000 psi). The chamber was 
cooled by immersion in an ice/water bath. Then the cell lysate was distributed into 2 ml 
tubes, cell debris and insoluble protein were removed by centrifugation on an 
ultracentrifuge (Heraeus Fresco 17, Thermo Scientific, Germany) at 13,000 rpm 
(17,000 × g) and 4 °C for 1 h.  About 90 ml supernatant were collected and stored at 4 °C 
until used. 
4.3.5.3 Cation exchange membrane chromatography 
45 ml supernatant was filtrated through a 0.2 µm sterile filter (Minisart® high flow; 
Sartorius Stedim Biotech, Göttingen, Germany) and loaded onto a strong cation exchange 
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membrane adsorber module (Sartobind S75; Sartorius Stedim Biotech, Göttingen, 
Germany) in an FPLC (fast protein liquid chromatography) system (Biologic Duo Flow; 
Bio-Rad, Munich, Germany). The membrane was equilibrated prior to use at room 
temperature with 10 ml equilibration buffer (25 mM sodium phosphate buffer pH 7.5, with 
3 mM DTT and 1 mM EDTA). Sample injection was carried out via an auxiliary pump 
(Econo pump EP-1; Bio-Rad, Munich, Germany) at a flow rate of 1.0 ml min-1. After that 
the membrane was washed with 15 ml of equilibration buffer at a flow rate of 1.0 ml min-1. 
FGF-2 was eluted by elution buffer 1 (25 mM sodium phosphate buffer pH 7.5, 1 M NaCl 
with 3 mM DTT and 1 mM EDTA) and a linear gradient of 0-1 M NaCl as shown in 
Fig.4.8. All the elution fractions were pooled and stored at 4 °C until the next step. The 
FPLC protocol for the cation exchange membrane chromatography is described in 
Appendix 6.5.1.1. 
 
Fig.4.8 Cation exchange membrane chromatography of clarified cell lysate. Elution was carried out 
with a linear gradient of 0-1 M NaCl. Elution of FGF-2 occurred at about 0.5 M NaCl. The arrow 
indicates FGF-2 peak. 
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4.3.5.4 Heparin-sepharose affinity chromatography 
42 ml FGF-2-containing solution collected from previous step was filtrated through the 
0.2 µm sterile filter and was directly applied to a heparin-sepharose column (HiTrap 
Heparin HP 5 ml; GE Healthcare, Munich, Germany) in the FPLC system. The column was 
pre-equilibrated at room temperature with 10 ml equilibration buffer. Sample injection was 
carried out via the auxiliary pump at a flow rate of 1.0 ml min-1. After loading the sample, 
the column was washed with 15 ml of equilibration buffer at a flow rate of 1.0 ml min-1 
until a stable baseline was reached. FGF-2 was eluted by elution buffer 2 (25 mM sodium 
phosphate buffer pH 7.5, 2.5 M NaCl with 3 mM DTT and 1 mM EDTA) and a linear 
gradient of 0-2.5 M NaCl as illustrated in Fig. 4.9.  
 
Fig.4.9 Heparin-sepharose affinity chromatography of FGF-2 containing fractions from cation 
exchange membrane chromatography. The arrows indicate FGF-2 peaks. Elution was carried out 
using a linear gradient of 0 to 2.5 M NaCl. Elution of FGF-2 occurred at 1.8 M NaCl (peak 1) and 
2.2 M NaCl (peak 2).  
As shown in Fig. 4.9, FGF-2 was eluted as a main peak (peak 1) and a minor peak (peak 2). 
SDS-PAGE and RP-HPLC analysis of both peak fractions showed that they were 
identically pure FGF-2 (data not shown). This was consistent with the observation of Iwane 
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et al. (1987) and Seeger et al. (1996), who also found two FGF-2 peaks when eluted from 
heparin-sepharose affinity column. Moreover, it was reported that the amino acid 
composition for the two peaks was also the same (Iwane et al., 1987). Therefore, both peak 
fractions were pooled and stored at 4 °C until the next step. The FPLC protocol for heparin-
sepharose affinity chromatography is described in Appendix 6.5.1.2. 
4.3.5.5 Salt removal by diafiltration 
The above two steps (section 4.3.5.3 and 4.3.5.4) were repeated once due to the limited 
binding capacity of the cation exchange membrane module and heparin-sepharose column.  
All FGF-2 fractions collected from heparin affinity chromatography were pooled for the 
next steps.  
32 ml FGF-2 solution was sterile filtrated and concentrated 20-fold using Vivaspin 20 
centrifugal concentrators (MWCO 3,000 Da; Sartorius Stedim Biotech, Göttingen, 
Germany) on the refrigerated centrifuge at 4,000 rpm (3,345 × g) and 4 °C. Remaining salt 
was removed by diafiltration of concentrated FGF-2 solution against 20 volumes 
exchanging buffer (20 mM Tris-HCl buffer pH 7.5, with 150 mM NaCl, 3 mM DTT and 1 
mM EDTA) for 2 times at 4,000 rpm (3,345 × g) and 4 °C. Finally, 25 ml retentate was 
collected. 
4.3.5.6 Anion exchange membrane chromatography 
Endotoxins are lipopolysaccharides which locate on the outer membrane of gram-negative 
bacteria. They can be released to the environment when the cells are destroyed and they are 
toxic to human beings and animals even at very low levels (Williams, 2007). Therefore 
endotoxins must be removed from the final product. Since FGF-2 is positively charged 
while endotoxins and DNAs are negatively charged at pH 7.5, it is possible to separate 
them by anion exchange membrane chromatography.  
Prior to use, the FPLC system was washed with 2 M KOH containing 30 % ethanol 
followed with pyrogen-free water to remove traces of endotoxins. An anion exchange 
membrane adsorber module (Sartobind Q75; Sartorius Stedim Biotech, Göttingen, 
Germany) was washed sequentially with 0.1 M KOH containing 20 % ethanol, 1.5 M NaCl 
and pyrogen-free water to make it endotoxin-free (Minobe et al., 1983). Then the 
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membrane was equilibrated with 10 ml of exchanging buffer. 25 ml FGF-2 solution from 
the diafiltration step were loaded onto the membrane at a flow rate of 0.5 ml min-1 (Fig. 
4.10) and the flow-through fractions were collected as pure FGF-2. The FPLC protocol for 
the anion exchange membrane chromatography is described in Appendix 6.5.1.3. 
 
Fig. 4.10 Endotoxin removal from FGF-2 solution by anion exchange membrane chromatography. 
Flow through fractions were collected as pure FGF-2. 
4.3.5.7 Endotoxin determination 
The endotoxin content of purified FGF-2 was determined by LAL assay as described in 
Appendix 6.3.5. As shown in Table 4.7, the anion exchange membrane chromatography 
was effective in removing endotoxins from FGF-2 solution. The final endotoxin content in 
the purified FGF-2 was 1.425 EU ml-1.  
Table 4.7 Comparison of endotoxin concentrations before and after anion exchange membrane 
chromatography 
 Endotoxin level (EU ml-1) Clearance rate (%) Protein recovery rate (%) 
before 37600   
after 1.425 99.99 ≥ 98 
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4.3.5.8 More about endotoxin 
The endotoxin level is critical for the proteins to be used for cell culture or clinical 
applications. In the final product, the endotoxin level was reduced to a very low value 
(Table 4.7) by anion exchange membrane chromatography, which was acceptable even for 
clinical applications (< 5 EU kg-1 h-1 as specified in European Pharmacopoeia (2007)).  
However, it should be pointed out, a certain amount of endotoxins could be still remained 
in the purified FGF-2. Since the positively charged protein can form complexes with the 
negatively charged endotoxins, demonstrating so-called masking of endotoxins. Moreover, 
the masked endotoxins can not be detected by the LAL test (Magalhães et al., 2007; Petsch 
and Anspach, 2000). Researches on the toxicity of protein-endotoxin complexes are 
inconsistent.  Rogy et al. (1994) reported that protein-bound endotoxins were still toxic as 
free endotoxins. While Emancipator et al. (1992) found that lipoprotein-endotoxin 
complexes were less toxic compared to free endotoxins.  
Petsch et al. (1998) reported that the masked endotoxins could be totally recovered  by 
digesting the protein with proteinase K. Garke et al. (2000) digested purified FGF-2 with 
proteinase K and found an increase in endotoxin concentration afterwards. But the 
endotoxin level was still lower than the critical point (< 5 EU kg-1 h-1). 
4.3.5.9 FGF-2 concentration determination 
The concentration of the pure FGF-2 was 1.52 mg ml-1 as determined by UV absorbance at 
280 nm (see Appendix 6.3.3.3). The total pure FGF-2 obtained was 52.28 mg. The 
calculated endotoxin content was 0.0009 EU µg-1 protein.  
4.3.5.10 FGF-2 formulation and lyophilization 
A carrier-free freeze-drying formulation was developed in order to meet the requirement of 
transportation and long term storage of the protein. The formulation contains 1-2 mg ml-1 
FGF-2, in 20 mM Tris-HCl buffer pH 7.5, with 150 mM NaCl, 3 mM DTT, 1 mM EDTA 
and 2 % (w v-1) sucrose.  
The formulated FGF-2 solution was sterile filtrated through the 0.2 µm filter and 
lyophilized (see Appendix 6.3.6). The lyophilized powder was stored at - 80 °C. 
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4.3.6 SDS-PAGE visualization of the downstreaming and purification process 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is a widely used 
approach to separate proteins according to their molecular weights. Gel preparation and 
running processes were described in Appendix 6.3.4.1.  The whole purification process was 
visualized by SDS-PAGE and shown in Fig.4.11. The gel was stained with blue silver stain 
solution (Candiano et al., 2004) (see Appendix 6.3.4.1.1).  
As shown in Fig. 4.11, after heparin-sepharose affinity chromatography the SDS-PAGE gel 
demonstrated only a single band of FGF-2 (Lane 6), which indicated that our new two-step 
purification process was effective in FGF-2 purification. And the polishing step has no 
negative effect on the protein purity (Lane 7). 
 
Fig.4.11 Purification of FGF-2 presented by SDS-PAGE visualized with Blue-silver stain solution. 
Lane 1, molecular weight marker; Lane 2, total cell lysate (dilution 1:20); Lane 3, soluble fractions 
of cell lysate (dilution 1:20); Lane 4, insoluble fraction of cell lysate (dilution 1:20); Lane 5, pooled 
fractions from cation exchange membrane chromatography (dilution 1:10); Lane 6, pooled fractions 
from heparin affinity chromatography (dilution 1:10); Lane 7, pooled fractions from anion 
exchange membrane chromatography (dilution 1:10). The arrow indicates the position of FGF-2. 
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4.3.7 FGF-2 recovery during the purification process 
The recovery rates of FGF-2 produced at different specific growth rates (0.35 h-1 and 
0.15 h-1) during sequential purification steps are shown in Fig. 4.12 and Fig.4.13, 
respectively. It is obvious that in both conditions about 23 % of soluble FGF-2 were lost 
during the purification process. Main protein loss was occurred in the centrifugation step 
and cation exchange membrane chromatography step. Since cells produce more soluble 
protein fractions at µset = 0.15 h-1, the finally FGF-2 recovery rate was 36 % while for µset = 
0.35 h-1 the final FGF-2 recovery rate was 22 %.  The FGF-2 contents were estimated by 
Bradford assay (see Appendix 6.3.3.1) and gel densitometry (see Appendix 6.3.3.2).  
 
Fig.4.12 Relative contents of FGF-2 during sequential purification steps (µset= 0.35 h-1). The protein 
contents were estimated by bradford assay and gel densitometry. 
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Fig.4.13 Relative contents of FGF-2 during sequential purification steps (µset= 0.15 h-1). The protein 
contents were estimated by bradford assay and gel densitometry. 
4.3.8 Improvement of the new purification process  
In this study, we developed an efficient protocol for cost-effective production of FGF-2. 
Reusable cation exchange membrane adsorber was used in the first purification step for fast 
and easy binding of FGF-2. Applying the pooled elution fractions from cation exchange 
membrane chromatography directly onto the heparin-sepharose column without dialysis 
was time-saving. The diafiltration step is faster than conventional dialysis process for salt 
removal, with protein loss less than 2 %. Last polishing step using high efficiency anion 
exchange membrane adsorber to remove endotoxins and DNAs result in protein recovery 
≥ 98 % and endotoxin level less than 0.001 EU µg-1 protein. The whole process yielded 
highly pure FGF-2 with a recovery rate of 22 % to 36 %. 
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4.3.9 Stabilizing of FGF-2 during the purification process 
FGF-2 is unstable and easy to be oxidized when contacts with air (Thompson and Fiddes, 
1991). Therefore, several methods have been used to keep FGF-2 in its reduced form 
during the purification process. All buffers and solutions used in the purification process 
were degassed by sonication to remove the oxygen dissolved in water. Moreover, DTT 
(Dithiothreitol) was added to all the buffers as a reducing agent.  
Due to air oxidation, DTT is relative unstable (half-life 10 h, at pH 7.5, 20 °C in 0.1 M 
potassium phosphate buffer) and oxidized DTT gives a strong UV absorption at 283 nm 
(Iyer and Klee, 1973). Since proteins have a maximum absorbance at 280 nm, a small 
increase of oxidized DTT amount could cause great change of protein concentration 
measured by UV absorption. However, the life time of DTT can be extended by storage at 
lower temperature and the addition of the metal chelating agent EDTA which can 
effectively inhibit disulfide bond formation (Foster et al., 1993). Therefore, all buffers were 
kept at 4 °C in the fridge with 3 mM DTT and 1 mM EDTA. At these conditions, the 
buffers could be kept for one week with negligible oxidation of DTT.  
By using the methods described above, FGF-2 was protected from oxidation and 
maintained its native conformation throughout the whole purification process (data not 
shown). 
4.4 Product identification 
4.4.1 MALDI-TOF MS 
Matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF 
MS) can be used for the determination and characterization of biomolecules, including 
proteins, peptides, oligosaccharides, etc. This method was used to further identify the 
molecular weight of FGF-2. The test was performed by the group of Prof. Dr. Ulrich 
Martin at Hannover Medical School (MHH) and the procedure for the sample preparation 
and operation are described in Appendix 6.3.4.2. 
Purified FGF-2 demonstrates a single peak at m/z = 17,124 which represents FGF-2 
monomer and no FGF-2 dimer is detected (Fig.4.15). 
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Fig. 4.15 MALDI-TOF MS of two different FGF-2 charges.  In both charges, a single peak at m/z = 
17,124 is observed. 
4.4.2 SDS-PAGE 
 
Fig. 4.14 SDS-PAGE of purified FGF-2 stained with silver. The arrow indicates the position of 
FGF-2. 
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The molecular weight of FGF-2 was identified with 12 % polyacrylamide gel using the 
recipe of Laemmli (1970). Gel preparation and running process were described in 
Appendix 6.3.4.1.  Purified FGF-2 visualized with silver stain (see Appendix 6.3.4.1.2) 
revealed a single band at about 17 kDa (Fig. 4.14).  
4.4.3 Fluorescence spectroscopy 
Fluorescence spectroscopy is a fast and effective method for the evaluation of FGF-2 
conformation properties. FGF-2 has only one tryptophan residue. In properly folded protein 
the emission of this tryptophan residue is completely suppressed and the emission spectrum 
is dominant by the fluorescence of tyrosine residues (λmax ≈ 306 nm). While unfolded FGF-
2 shows a strong increase of tryptophan fluorescence (λmax ≈ 350 nm) together with the 
tyrosine fluorescence (Estape et al., 1998).  The fluorescence spectrum of purified FGF-2 
demonstrates an asymmetry peak at 306 nm (Fig. 4.16) which indicates the purified FGF-2 
is completely folded. The analytical protocol is described in Appendix 6.3.4.4. 
 
Fig.4.16 Base-line corrected fluorescence spectrum of purified FGF-2. The asymmetric peak at 
306 nm indicates the properly folded state of FGF-2. 
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4.4.4 Western blot analysis  
Western blot analysis is based on the specific binding of FGF-2 to the monoclonal anti-
human-FGF-2 antibody.  The procedure is described in Appendix 6.3.4.3. Western blot 
analysis of purified FGF-2 demonstrates a single band at about 17 kDa (Fig. 4.17). 
 
Fig.4.17 Western blot analysis of purified FGF-2. Lane 1, molecular weight marker; Lane 2, 
purified FGF-2. 
4.4.5 RP-HPLC 
 
Fig.4.18 RP-HPLC analysis of purified FGF-2. 
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Reverse phase-high performance liquid chromatography (RP-HPLC) was used to determine 
the purity of purified FGF-2. The system construction and chromatography conditions are 
described in Appendix 6.3.4.5. The HPLC protocol is presented in Appendix 6.5.2. HPLC 
analysis of purified FGF-2 revealed that the protein was eluted by 34 % acetonitrile as a 
single peak, which was consistent with the report of Squires et al. (1988). The peak at about 
5.7 min refers to DTT. The purity of FGF-2 calculated by area normalization method was 
98.2 %. 
4.5 Biological activity test  
4.5.1 Bioactivity test performed at the TCI 
The activity test was performed by Dr. Ingrida Majore and Antonina Lavrentieva at the TCI 
on the proliferation of mesenchymal stem cell-like cells and NIH-3T3 fibroblast cells.  
4.5.1.1 Bioactivity test on mesenchymal stem cell-like cells 
The biological activity of purified FGF-2 was tested using mesenchymal stem cell-like cells 
obtained from human umbilical cord.  Mesenchymal stem cell-like cells were seeded in 24-
well-plates at a density of 500 cells cm-2 and cultivated in αMEM (minimum essential 
medium, alpha modified) enriched with 1 % human serum, 10 µg ml-1 insulin, 5.5 µg ml-1 
transferrin, 6.7 pg ml-1 sodium selenite, 2 mg ml-1 human albumin, 50 µg ml-1 gentamicin 
and appropriate amounts of FGF-2 varying in the range from 0 to 1 ng ml-1.  Medium was 
changed three times a week.  9 days after cell seeding, the indirect determination of the 
number of viable cells was performed using CellTiter-Blue® cell viability assay (Promega, 
Southampton, UK) according to the manufacturer’s instructions. Commercially available 
FGF-2 (ref. 167100-18B-B, tebu-bio, Offenbach, Germany) was applied as a positive 
control.  
The produced FGF-2 demonstrated a high activity on the proliferation of mesenchymal 
stem cell-like cells and gave an EC50 (half maximal effective concentration) of 0.13 ng ml-1, 
while the EC50 of a commercially available FGF-2 was 0.21 ng ml-1 as shown in Fig.4.19. 
Our purified FGF-2 gave better results than the commercial one.  
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Fig. 4.19 Dose-dependent proliferation of mesenchymal stem cell-like cells in the presence of   
FGF-2. 
4.5.1.2 Bioactivity test on NIH-3T3 cells 
Biologic activity of FGF-2 was also tested by a dose-dependent cell proliferation assay on 
NIH-3T3 fibroblast cells (DSMZ, Deutsche Sammlung von Mikroorganismen und 
Zellkulturen GmbH, Braunschweig, Germany). Cells were seeded in 96-well-plates in 
culture medium (DMEM, Sigma-Aldrich, Taufkirchen, Germany) supplemented with 
10 % (V V-1) FCS (fetal calf serum) and 1 % penicillin-streptomycin (PAA Laboratories 
GmbH, Pasching, Austria) with an initial cell density of 4,000 cells well-1. After seeding, 
cells were starved for 24 h in DMEM with 1 % FCS and then cultivated in FGF-2-
containing media for 52 h. Cells cultivated in culture medium without FGF-2 served as 
negative control.  
For the indirect estimation of cell proliferation, CellTiter-Blue® cell viability assay 
(Promega, Southampton, UK) was performed. The metabolic capacity of viable cells was 
measured as a result of the reduction of the indicator dye resazurin into highly fluorescent, 
pink colored resorufin (Ex 579 nm/Em 584 nm), according to the manufacturer´s 
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instructions (Fig. 4.20). Fluorescence measurements were performed on the Fluoroskan 
Ascent microplate reader (Thermo Scientific, Dreieich, Germany) and results are presented 
as percentage to the negative control. 
 
Fig. 4.20 Changing of CellTiter-Blue® reagent color after 2 h incubation at 37 °C (pink color 
indicates a higher rate of dye reduction because of a higher cell number). 
 
Fig.4.21 Dose-dependent proliferation of NIH-3T3 cells in the presence of FGF-2. 
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The adding of FGF-2 resulted in significant increase of NIH-3T3 cell division and gave an 
EC50 of 0.10 ng ml-1 as shown in Fig.4.21. The EC50 was calculated according to the 
method of Alexander et al. (1999). This was consistent with other reports on the mitogenic 
activity of recombinant FGF-2 on 3T3 fibroblast cells (Fox et al., 1988; Garke et al., 2000; 
Gasparian et al., 2009; Squires et al., 1988), which have an EC50 of 0.15 to 3 ng ml-1. 
4.5.2 Bioactivity test performed at MHH 
In order to further test the bioactivity of purified FGF-2, the activity tests were also 
performed at Hannover Medical School (MHH) on a large variety of cells. 
4.5.2.1 Activity test on neuronal differentiation of PC12 cells 
The activity test was performed by Silvana Taubeler-Gerling, Dipl.-Biol. Maike Wesemann 
and PD Dr. Kirsten Haastert at the Institute of Neuroanatomy, MHH. The neuronal 
differentiation activity of FGF-2 was tested on PC 12 cells. A commercial FGF-2 
(PeproTech Inc., Rocky Hill, USA) was used as positive control. The results are shown in 
Fig.4.22-Fig.4.25. The neuronal differentiation observed with purified FGF-2 was similar 
to the commercial FGF-2 (Fig. 4.24, Fig. 4.25). 
 
Fig. 4.22 PC 12 cells without FGF-2 in the medium were used as negative control. The cells were 
cultivated in vitro for 6 days and no neuronal differentiation was observed. 
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Fig. 4.23 PC 12 cells supplemented with commercial FGF-2 to a concentration of 100 ng ml-1 in the 
medium. The cells were cultivated in vitro for 6 days and show neuronal differentiation by 
protruding cell processes. 
 
Fig. 4.24 PC 12 cells supplemented with purified FGF-2 to a concentration of 50 ng ml-1 in the 
medium. The cells were cultivated in vitro for 6 days and show neuronal differentiation similar to 
the commercial FGF-2. 
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Fig. 4.25 PC 12 cells supplemented with purified FGF-2 to a concentration of 100 ng ml-1 in the 
medium. The cells were cultivated in vitro for 6 days and show neuronal differentiation similar to 
the commercial FGF-2. 
4.5.2.2 Activity test on pluripotent cell culture 
This activity test was performed by Susann Müller, Dr. Robert Zweigerdt and Prof. Dr. 
Ulrich Martin at the department of Cardiac-, Thoracic-, Transplantation and Vascular 
Surgery, REBIRTH-Center for Regenerative Medicine, MHH.  
Pluripotent stem cells (PSC) including ESC and iPSC (induced pluripotent stem cell) are 
important research subjects since the mechanisms underlying cellular differentiation, 
expansion, and self-renewal can be studied along with differentiated tissue development 
and regeneration in vitro (Cantz and Martin, 2010; Zweigerdt, 2009). Furthermore, human 
PSC hold promise for cell and tissue replacement approaches to treating human diseases. 
The rhesus and the cynomolgus monkey are clinically relevant primate models that will 
likely be required to bring these clinical applications to fruition (Schwanke et al., 2006). 
Primates ESC share a number of properties with human ESC including their sensitivity to 
in vitro culture conditions and particularly the FGF-2 content in the medium, which is a key 
factor in keeping the cells pluripotent. Thus, we have applied both, primate ESC and human 
iPS cell lines to test the biological activity of the FGF-2 generated in this study. 
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Feeder-dependent culture of undifferentiated human cord blood endothelial cell-derived 
iPSC (Haase et al., 2009), rhesus ESC (Schwanke et al., 2006) and cynomolgus monkey 
ESC (MF12; (Olmer et al., 2010)) were cultured and expanded under standard hESC 
culture conditions (Olmer et al., 2010; Singh et al., 2010). In brief, cells were grown 
mitotically inactivated fibroblast in KnockOutTM DMEM supplemented with 20 % 
KnockOutTM serum replacement, 1 mM L-glutamine, 0.1 mM ß-mercaptoethanol, 1 % 
nonessential amino acid stock (all from Invitrogen,  Karlsruhe, Germany), and 4 ng ml-1 
commercial FGF-2 (positive control; R&D Systems, Wiesbaden, Germany) or respective 
concentration of FGF-2 generated in this study (test FGF-2) as indicated in the results. 
To assess the seeding efficiency and pluripotency markers expression, cells were passaged 
in the respective FGF-2 concentration for 6 passages on fibroblasts and then seeded in 
decreasing concentration on gelatine coated plates in a 24-well format. After 4 days cells 
were fixed, H&E stained (hematoxylin and eosin stain) and the cell density was analysed 
by light microscopy.  
For flow cytometry, single cell suspensions were prepared by collagenase digest. Cells 
were incubated in a 96 v-bottom plate with an SSEA 4 (stage-specific embryonic antigen 4) 
specific primary antibody (1:68, MC-813-70, Developmental Studies Hybridoma Bank 
University of Iowa) and corresponding isotype controls for 30 min at 4 °C. After washing, 
cells were incubated with a secondary antibody, CyTM3-labeled donkey anti-mouse IgG 
(1:200; Jackson Immunoresearch Laboratories, Suffolk, UK) for 30 min at 4 °C. The cells 
were analyzed using a FACSCalibur cell analyzer (BD Bioscience, Heidelberg, Germany). 
Data were further processed using WinMDI 2.9 software.  
Primate ESC and human cord blood-derived iPSC (Haase et al., 2009) were culture for 6 
passages either in purchased FGF-2 at 4 ng ml-1 (positive control), in our generated test 
FGF-2 at 2, 4 and 8 ng ml-1 or in FGF-free conditions (negative control). Thereafter (at 
passage 7) cells were seeded in decreasing concentration on gelatine coated plates in the 
presence of the respective FGF-2 concentration and quality and seeding efficiency was 
semi-quantitatively assessed 4 days later. As exemplarily shown for rhesus ESC in Fig. 
4.26A, seeding efficiency and cell growth in our produced FGF-2 was at least equivalent to 
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the commercially available FGF-2 even at the lowest concentration tested (respective data 
for cynomolgus ESC and human iPSC not shown). 
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Fig. 4.26 Biological activity of FGF-2 on pluripotent cells. (A): Assessment of seeding efficiency 
and expansion of rhesus ESC. After 6 passages in the respective FGF-2 concentration, cells were 
seeded at 5-100 k cells per well and cultured for 4 days in the respective FGF-2 concentration as 
indicated. Thereafter, H&E staining was performed and cells were analysed by light microscopy. 
(B): Flow cytometry analysis (histograms) documenting the percentage of SSEA4 positive rhesus 
ES cells after 6 passages in the presence of the respective FGF-2 concentration. The isotype control 
is indicated in red.  
To assess pluripotency of the cells, flow cytometry specific to the pluripotency-associated 
surface marker SSEA4 was performed after 6 passages in the respective FGF-2 
concentration, as described above. With our test FGF-2, > 90 % of the cells were SSEA4 
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positive at all concentrations as compared to about 86 % positive cells observed in the 
control FGF-2 (Fig. 4.26B). As expected, the proportion of SSEA4 positive cells dropped 
to only about 20 % in the absence of the growth factor. These data strongly suggest the 
optimal biological activity of the generated FGF-2. 
4.5.2.3 Other bioactivity tests  
The bioactivity of our produced FGF-2 was also tested successfully by the group of Dr. 
Axel Schambach at MHH, Dr. Inga von Ahsen at the Small Animal Clinic, University of 
Veterinary Medicine Hannover (TiHo) and also the group of Prof. Joseph Itskovitz-Eldor at 
the Stem Cell Center, Faculty of Medicine, Technion (Israel Institute of Technology), 
Israel. 
4.5.3 Comparison of bioactivity of FGF-2 produced at different growth rates   
Growth rates can greatly affect many metabolic processes of E. coli like cell growth, 
acetate formation (Button, 1985; Hempfling and Mainzer, 1975; Shiloach et al., 1996). 
Some researches also reported it could affect the activity of produced recombinant protein 
(Hellmuth et al., 1994; Kazan et al., 1995). Therefore, the biological activity of FGF-2 
produced at two different growth rates (0.35 and 0.15 h-1) was tested and compared. 
 
Fig. 4.27 Comparison of bioactivity of FGF-2 produced at different growth rates. Error bars indicate 
the standard deviation from 3 measurements. 
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The bioactivity tests were performed as described in section 4.5.1.2. NIH-3T3 cells 
proliferation at different concentration of FGF-2 is shown in Fig. 4.27. The calculated EC50 
for FGF-2 produced at specific growth rate of 0.35 h-1 was 0.11 ng ml-1 and for 0.15 h-1 was 
0.12 ng ml-1. There seems to be no significant difference between them. That might because 
the purification process was designed for isolating FGF-2 from the soluble fractions which 
were properly folded protein, while the misfolded protein fractions (insoluble as inclusion 
bodies) were discarded before the purification process. Therefore, at different growth rate 
only the FGF-2 recovery rate was changed, the activity was the same. 
4.5.4 Effect of lyophilization on the bioactivity of FGF-2 
Dehydration process can lead to remarkable conformation changes of most native proteins 
(Wang, 2000). These conformation changes can be detected and analyzed by FTIR (Fourier 
transform infrared) spectroscopy (Costantino et al., 1995; Dong et al., 1995a; Luthra et al., 
2007). By comparing second-derivative FTIR spectra of the protein in aqueous solution and 
dry state, structure damage caused by freeze-drying could be qualitatively determined. 
 
Fig.4.28 Comparison of NIH-3T3 cell proliferation in the presence of FGF-2 solution and 
lyophilized FGF-2. Error bars indicate the standard deviation from 3 measurements.  
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Prestrelski et al. (1993) investigated the conformational changes of FGF-2 when 
lyophilized in Tris-HCl buffer. They found moderate changes in certain bands (e.g. loss of 
band at 1657cm-1 and band broadening at 1643 cm-1) after lyophilization and these changes 
could be prevented by adding sucrose as a stabilizer. They considered this phenomenon 
could be explained by the water substitute hypothesis (Carpenter and Crowe, 1989). A 
possible mechanism could be that sucrose can form hydrogen bonds with FGF-2 and 
replaced the water which was lost during drying process. Therefore, unfolding of the 
protein due to dehydration can be inhibited. But till now, the actual protection mechanism 
is still not completely revealed (Chang et al., 2005; Rey and May, 2004).  
In our formulation, 2 % (w v-1) sucrose was added to the FGF-2 solution (1.52 mg ml-1 
FGF-2 in 20 mM Tris-HCl pH 7.5, with 150 mM NaCl, 3 mM DTT, 1 mM EDTA) as a 
cryoprotectant, which resulted in no significant change in bioactivity was observed before 
and after dehydration as shown in Fig. 4.28. 
4.6 Preliminary stability test of lyophilized FGF-2 
4.6.1 Residual water content determination 
The residual water content usually determines the long-term stability of lyophilized 
proteins (Franks, 1992; Hatley and Franks, 1991).  Water can affect protein stability by 
acting as reaction medium or reactant (Shalaev and Zografi, 1996). Water content of 
lyophilized proteins can be determined by several methods, including loss-on-drying, Karl 
Fischer titration, thermal gravimetric analysis (TGA), gas chromatography (GC) and NIR 
(near infrared). 
The residual water content in lyophilized FGF-2 powder was determined by loss-on-drying 
method. 5 random tubes were chosen from a batch of lyophilized FGF-2.  The tubes were 
dried at 80 °C till a constant weight was reached. The weight loss was considered to be 
residual water. The water content was presented as the weight of water to the weight of 
lyophilized powder and summarized in Table 4.8. Wu et al. (1998) have investigated the 
degradation of FGF-2 lyophilized with sugar and found that lyophilized FGF-2 was stable 
unless the water content is above 2 %.  Our formulation has successfully met this 
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requirement with average residual water content of 1.90 % and a standard deviation of 
0.17 %. 
Table 4.8 Residual water contents of five random chosen lyophilized FGF-2 samples. 
Tube 1 2 3 4 5 Average 
Residual water 
content (%) 
1.83 1.66 1.96 1.89 2.19 1.90 ± 0.17 
4.6.2 Preliminary stability test 
A stability test is used to study the quality of a pharmaceutical product under specific 
storage conditions over a certain time  period. It could be used to study the influence of the 
environmental factors (e.g. temperature, humidity,  agitation and light) on the quality of a 
drug product. From the stability test a shelf-life of the pharmaceutical product could be 
estimated and the best storage conditions could be identified (Mollica et al., 1978). 
In this test, a multiple isothermal stability method was used. Formulated FGF-2 aliquots 
(1 ml) were lyophilized in 15 ml screw-caped, polypropylen centrifuge tubes according to 
Appendix 6.3.6. After that, 14 tubes were taken out and placed in controlled-temperature 
unit at 37 °C (4 tubes), 4 °C (5 tubes) and room temperature (5 tubes).  At set intervals one 
tube was removed and kept at -80 °C until analyzed.  
The quantitative measurement of FGF-2 content was performed by RP-HPLC as described 
in Appendix 6.3.4.5. A 0 day sample of lyophilized FGF-2 was used as reference. The 
results are shown in Table 4.9. It is clear that no significant change of FGF-2 content was 
observed during 17 days storage at 37 °C, 1 month at room temperature or 2 month at 4 °C.  
Moreover, no FGF-2 dimers or degradation products were detected during the HPLC 
analysis (data not shown). Fluorescence spectrum of all the testing samples indicated all the 
samples were in its native conformation (data not shown). So it could be conclude that the 
lyophilized FGF-2 powder was stable after 17 days storage at 37 °C, 1 month at room 
temperature or 2 month at 4 °C.  
However, physical property changes of the lyophilized FGF-2 powder (i.e. collapse, 
volume decrease) were observed at all storage conditions. That might because the 
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lyophilized protein samples were sealed under conventional atmosphere, the moisture in the 
air could react with the lyophilized protein and reduce its stability. If we extend the stability 
test period, decreases in the FGF-2 content should be seen. Therefore, it is recommended to 
store lyophilized FGF-2 at -20 °C to -80 °C. Supposing we can seal the lyophilized protein 
under nitrogen or vacuum, the storage time might be further extended.  
Table 4.9 Stability data by RP-HPLC of FGF-2 in polypropylene tubes at different temperatures. 
Storage time 
(days) 
% FGF-2 remaininga 
37 °C Room temperature 4 °C 
0 100.0 100.0 100.0 
4 95.4   
8 96.0 99.4  
12 97.8 106.4 104.3 
17 99.3 101.8  
22  110.9  
24   106.9 
29  98.8  
36   102.6 
51   104.7 
59   117.8 
a Percentage compare to 0 day. Percentage was calculated based on FGF-2 peak area.  
4.7 Summary and conclusion 
In this work, a new production process of FGF-2 from recombinant E. coli was described. 
Effective production of FGF-2 was achieved by fed-batch cultivation of E. coli BL21on a 
defined medium. Two different specific growth rates were used (0.35 h-1 and 0.15 h-1) and 
final FGF-2 expression level reached 42 and 31 mg g-1 dry cell, respectively. Due to the 
high time-space yield of soluble protein (0.056 g l-1 h-1), the higher specific growth rate 
(0.35 h-1) was considered to be the better condition for FGF-2 production.  
The downstreaming process was performed by disrupt the cells with a high pressure 
homogenizer followed by centrifugation. The clarified cell lysate was purified by a new 
combination of cation exchange membrane chromatography and heparin-sepharose affinity 
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chromatography. Endotoxins and DNAs were removed by passing the protein solution 
through an anion exchange membrane module. Finally, purified FGF-2 was formulated 
with sucrose and lyophilized for long-term storage. The overall yield of purified protein 
was about 22 % (µset = 0.35 h-1) and 36 % (µset = 0.15 h-1), respectively. 
The purified FGF-2 was successfully identified by MALDI-TOF MS, SDS-PAGE, Western 
blot analysis, Fluorescence spectroscopy and RP-HPLC. The high yield, low-cost and time 
saving steps make this process easy to scale up for a large-scale production. 
The mitogenic activity of the final product was compared with a commercially avalible 
FGF-2 (ref. 167100-18B-B, tebu-bio, Offenbach, Germany) on the proliferation of 
mesenchymal stem cell-like cells at the TCI. The activity of purified FGF-2 (EC50 = 
0.13 ng ml-1) was even higher than the commercial one (EC50 = 0.21 ng ml-1).  Activity test 
of purified FGF-2 on the proliferation of NIH-3T3 fibroblast cells also showed extremely 
high activity (EC50 = 0.10 ng ml-1) which was comparable to the activity of a commercially 
available FGF-2 on 3T3 cells (EC50 = 0.1-1.0 ng ml-1, Recombinant human FGF-2, 
155 AA, Invitrogen, Karlsruhe, Germany). 
The bioactivity of purified FGF-2 was also tested successfully on neuronal differentiation 
of PC 12 cells as well as on keeping primate ESC and human iPSC cells pluripotent at 
MHH. Other activity tests performed at cooperation institutes also obtained positive results 
which proved it has great potential for application in cell culture. 
A preliminary stability test demonstrated lyophilized FGF-2 powder has a residual water 
content of 1.9 %. And the freeze-dried protein was stable after 17 days storage at 37 °C, 1 
month at room temperature or 2 month at 4 °C. 
4.8 Outlook and future work 
Future work could include the following aspects: 
For FGF-2 production, different expression systems could be tested in order to get more 
soluble fractions or absolutely soluble FGF-2. Plasmid stability and ribosome content of the 
cells during fed-batch cultivation should be tested to determine the best specific growth rate 
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for FGF-2 production. Further fed-batch cultivation up to 10 l and 30 l could be interest for 
large-scale production of FGF-2. 
For the downstreaming process, ultrafiltration could be tested instead of centrifugation for 
the separation of cell lysate. 
For the lyophilization, seal the lyophilized protein in centrifuge tubes under nitrogen or 
vacuum environment instead of conventional air condition could further extend its storage 
period. Further sterile lyophilization process should be developed in order to produce sterile 
lyophilized FGF-2.  
Prior to possible clinical applications, further long-term stability test of lyophilized FGF-2 
should be performed according to FDA guidelines. And further experiments should be 
carried out to determine the DNA and heparin content of the final product. Since heparin 
can leak from the heparin-sepharose affinity column and it could inhibit blood coagulation. 
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6. Appendix 
6.1 Chemicals and buffers 
6.1.1 Chemicals 
All chemicals and reagents were purchased from Sigma-Aldrich (Taufkirchen, Germany) 
unless specified elsewhere. Deionized, pyrogen-free water was obtained from an ARIUM 
UF 611 water system (Sartorius Stedim Biotech, Göttingen, Germany). 
6.1.2 Buffers and solutions 
6.1.2.1 Buffers for FGF-2 purification 
All buffers for FGF-2 purification are filtrated with 0.2 µm filters and then degassed by 
sonication for 30 min. After that the buffers are stored in the refrigerator at 4 °C until used.  
Lysis buffer, 25 mM phosphate buffer pH 7.5 and 100 mM NaCl 
Dissolve 0.1298 g NaH2PO4H2O, 0.5764 g Na2HPO4, 1.17 g NaCl, 0.0744 g EDTA 
disodium salt  dihydrate, 0.0926 g DTT, 0.05 g MgCl2·7H2O and 200 U of benzonase in 
200 ml deionized water.  
Equilibration buffer, 25 mM phosphate buffer pH 7.5 
Dissolve 0.6491 g NaH2PO4H2O, 2.8821 g Na2HPO4, 0.4628 g DTT and 0.3722 g EDTA 
disodium salt  dihydrate in 1000 ml deionized water. 
Elution buffer 1, 25 mM phosphate buffer pH 7.5 + 1 M NaCl 
Dissolve 0.3245 g NaH2PO4H2O, 1.4411 g Na2HPO4, 0.2314 g DTT, 0.1861 g EDTA  
disodium salt  dihydrate and 29.25 g NaCl in 500 ml deionized water. 
Elution buffer 2, 25 mM phosphate buffer pH 7.5 + 2.5 M NaCl 
Dissolve 0.3245 g NaH2PO4H2O, 1.4411 g Na2HPO4, 0.2314 g DTT, 0.1861 g EDTA  
disodium salt  dihydrate and 73.125 g NaCl in 500 ml deionized water. 
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Exchanging buffer, 20 mM Tris-HCl pH 7.5 and 150 mM NaCl 
Dissolve 1.2114 g Tris base in 100 ml of deionized water and adjust to the desired pH with 
concentrated HCl. Add 4.3875 g NaCl and 0.2314 g DTT, 0.1861 g EDTA disodium salt 
dihydrate. Mix and add deionized water to 500 ml. 
6.1.2.2 Buffers and solutions for SDS-PAGE and stain 
Sample loading buffer 
Bromphenolblue buffer consists of 20 mM Tris-HCl pH 6.8, 2 mM EDTA, 5 % (v v-1) SDS 
and 0.02 % (w v-1) bromphenolblue. The sample loading buffer comprises of 
bromphenolblue buffer, 2-mecaptoethanol and 55 % (v v-1) glycerol with a volume ratio of 
3:1:1. 
Running buffer (1× TGS buffer) 
SDS-PAGE running buffer consists of 25 mM Tris base, 192 mM glycine and 0.1 % (w v-1) 
SDS, pH 8.3. 
Silver destaining-fix solution 
Silver destaining-fix solution consists of 80 ml acetic acid, 400 ml ethanol and 400 ml 
deionized water. 
Farmers Reducer solution 
Dissolve 0.1 g sodium thiosulfate and 0.1 g potassium ferricyanide in 100 ml deionized 
water. 
6.1.2.3 Buffers for western blot analysis 
Transfer buffer 
Transfer buffer comprises of 25 mM Tris base, 192 mM glycine and 10 % (v v-1) ethanol, 
pH 8.3. 
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TBS buffer 
TBS buffer consists of 25 mM Tris-HCl pH 7.4 and 150 mM NaCl. 
TBST buffer 
TBST buffer consists of 25 mM Tris-HCl pH 7.4, 150 mM NaCl and 0.5 % (v v-1) Tween 
20. 
Block buffer  
Block buffer comprises of 25 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 % (w v-1) BSA and 
0.5 % (v v-1) Tween 20. 
AP (alkaline phosphatase) buffer (10×) 
AP buffer consists of 100 mM Tris, pH 9.5. 
Color-Development-Reagent 
Color-Development-Reagent comprises of 25 ml AP-buffer and 500 µl BCIP (5-bromo-4-
chloro-3 indolylphosphate)/NBT (nitroblue tetrazolium) substrate. 
6.2 Media 
6.2.1 Medium for cultivating E. coli K1 
6.2.1.1 Preculture medium 
The complex medium consists of 10 g l-1 yeast extract and 10 g l-1 tryptone. 
6.2.1.2 Reactor cultivation medium 
The composition of the synthetic medium for batch and feed solution were given in Table 
6.1. 
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Table 6.1 Medium composition for reactor cultivation of E. coli K1 
Components  Batch medium Feed solution 
Glucose 18a / 5 g l-1 100 g l-1 
K2HPO4 6.665 g l-1  
KH2PO4 0.25 g l-1  
NaCl 1.2 g l-1  
K2SO4 1.1 g l-1  
(NH4)2SO4 10 g l-1 27.5 g l-1 
MgSO4·7H2O 0.15 g l-1 1.5 g l-1 
FeSO4·7H2O 0.001 g l-1 0.01 g l-1 
CuSO4·5H2O 0.001 g l-1 0.01 g l-1 
CaCl2·2H2O 0.013 g l-1 0.026 g l-1 
a For batch cultivation only 
6.2.2 Medium for cultivating E. coli BL21 
6.2.2.1 Preculture medium 
The Luria-Bertani (LB) medium contains 10 g l-1 of tryptone, 10 g l-1NaCl and 5 g l-1 of 
yeast extract. 
6.2.2.2 Reactor cultivation medium 
A synthetic medium is prepared with the following components (Table 6.2 ). 
Table 6.2 Composition of medium and feed solution for reactor cultivation of E. coli BL21 
Components Batch medium  Feed solution 
Glucose 4.0 g l-1 100 g l-1 
KH2PO4 13.3 g l-1  
(NH4)2HPO4 4.0 g l-1  
MgSO4·7H2O 1.2 g l-1 10 g l-1 
Citric acid 1.7 g l-1  
Na2EDTA·2H2O 14.1 mg l-1 13 mg l-1 
CoCl2·6H2O 2.5 mg l-1 4.0 mg l-1 
MnSO4·H2O 12.8 mg l-1 20.1 mg l-1 
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CuSO4·5H2O 2.2 mg l-1 3.4 mg l-1 
H3BO3 3.0 mg l-1 4.7 mg l-1 
Na2MoO4·2H2O 2.1 mg l-1 4.0 mg l-1 
Zn(CH3COO)2·2H2O 33.8 mg l-1 16.0 mg l-1 
Fe(III)citrate 100.8 mg l-1 40.0 mg l-1 
Thiamine·HCl 4.5 mg l-1 4.5 mg l-1 
Antifoam 0.1 ml l-1  
Kanamycin 20 mg l-1 20 mg l-1 
6.3 Methods 
6.3.1 Off-line parameters determination 
6.3.1.1 Dry cell weight determination 
Dry cell weights (DCW) were determined approximately every hour by centrifuging 
(17,000 × g, 3 min) 2 ml aliquots of the culture broth collected in pre-weighted tubes. Then 
the pellets were washed with deionized water and dried for 24 h at 80 °C. The dry cell 
weights were determined afterwards gravimetrically.  
6.3.1.2 Glucose determination 
The off-line glucose concentration was measured roughly every hour using an YSI 2700 
select biochemistry analyzer (Yellow Springs Instruments, Ohio, USA). In order to get 
more precise measurements in the fed-batch phase, the off-line glucose concentrations were 
determined by RQflex® 2 reflectometer (Merck KGaA, Darmstadt, Germany), with test 
strips (Glucose-test, 1-100 mg l-1; Merck KGaA, Darmstadt, Germany). 
6.3.1.3 Acetate determination 
Acetate concentrations were determined by a gas chromatography (Shimadzu GC-14B; 
Shimadzu, Duisburg, Germany) equipped with a flame ionization detector. 6 standard 
acetate concentrations (0.05 g l-1, 0.1 g l-1, 0.5 g l-1, 1.0 g l-1, 2.5 g l-1 and 5.0 g l-1) were 
used and n-propanol was used as the internal standard.  The amount of acetate in the 
samples was calculated by the Shimadzu Class VPTM chromatography software version 4.2 
(Shimadzu, Duisburg, Germany). 
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6.3.2 Polysialic acid quantification 
A modified thiobarbituric acid (TBA) method was used for the quantification of PSA. In 
the first step, 50 µl sample was hydrolyzed by 200 µl of 50 mM H3PO4 and incubated at 
70 °C for 18 h, followed by neutralization with 100 µl 0.1 M NaOH. The oxidation of sialic 
acid residues was performed by adding 100 µl periodic acid (0.2 M) in 0.5 % (v v-1) H3PO4. 
The oxidation was stopped by adding 500 µl NaAsO2 solution (0.38 M) in 2 % (v v-1) 
H2SO4 after 30 min of incubation at 37 °C. Finally, 500 µl thiobarbituric acid solution 
(0.2 M) in 1.2 % (v v-1) NaOH was added to the sample and heated to 95 °C for 13 min. 
The pink dye was extracted by cyclohexanone and diluted to a proper range. The absorption 
was measured at 549 nm and PSA content were calculated from the standard curve. 
6.3.3 FGF-2 quantification 
6.3.3.1 Bradford assay 
10 µl of the samples and different concentrations of BSA (bovine serum albumin) standards 
(1000 µg ml-1, 750 µg ml-1, 500 µg ml-1, 250 µg ml-1, 200 µg ml-1, 100 µg ml-1 and 
50 µg ml-1) were added to a 96-well plate and mixed with 300 µl of Bradford-reagent 
(0.1 g l−1 Coomassie-brilliant-blue G250, 50 ml l-1 ethanol (96 %), 100 ml l-1 phosphoric 
acid (85 %)). Then the plate was shaken for 30 s and incubated at 37 °C for 10 min. 
Afterwards the absorption was measured at 595 nm. Protein concentrations were calculated 
from the BSA standard curve. 
6.3.3.2 Gel-densitometry  
SDS-PAGE gels were stained with blue silver stain solution over night, and then gels were 
destained in water for 16 h until a clear background was reached (Fig. 6.1). Afterwards, 
gels were scanned on a HP scanjet 2000 scanner. Gel-pro® Analyzer 6.0 software (Media 
Cybernetics, Marlow, UK) was used for gel image analysis to determine the total 
integration optical density (IOD) of the protein bands. Purified FGF-2 (750 µg ml-1,  
500 µg ml-1, 250 µg ml-1, 200 µg ml-1, 100 µg ml-1) were used as standards and a linear 
correlation between the FGF-2 concentration and IOD was obtained (Fig. 6.2). FGF-2 
concentrations in the samples were calculated from the standard curve. 
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Fig. 6.1 Typical SDS-PAGE gel for quantitative estimation of FGF-2 concentrations. Lane 1, 
Molecular weight marker; Lane 2-6,  Purified FGF-2 as standards: 750 µg ml-1, 500 µg ml-1,  
250 µg ml-1, 200 µg ml-1, 100 µg ml-1; Lane 7, total cell lysate (dilution 1:16); Lane 8, soluble 
fraction of cell lysate (dilution 1:16). 
 
Fig. 6.2 Typical calibration curve of FGF-2 concentration against total integration optical density. 
The amount of FGF-2 in the samples were calculated from the curve. 
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6.3.3.3 UV absorbance at 280 nm 
The concentration of purified FGF-2 was determined by measuring UV absorbance at 280 
nm on a UV-Vis spectrophotometer (Cary 50, Varian Deutschland GmbH, Darmstadt, 
Germany) with a quartz cuvette (Type 6040-UV, Hellma GmbH, Müllheim, Germany). 
15,930 M-1 cm-1 was used as the molar extinction coefficient. This value was calculated 
from the FGF-2 amino acid sequence on the ExPASy website using the ProtParam program 
(http://www.expasy.org/tools/protparam.html). 
6.3.4 FGF-2 identification 
6.3.4.1 SDS-PAGE  
1. Carefully clean the glass plates and assembling the casting stands following the Mini-
PROTEAN® Tetra (Bio-Rad, Munich, Germany) instruction manual.    
2. Mix solutions for separating gels as shown in Table 6.3 and pour the mixture into the 
plates. 
Table 6.3 Recipe for SDS-PAGE gel preparation. 
 
 
 
 
 
 
 
 
3. Overlay the gel with deionized water and allow gel to polymerize, remove the water 
afterwards. 
Components Separating gel (12 %) Stacking gel (6 %) 
Acrylamid/Bisacrylamid-
solution (37.5:1) 
3.0 ml 0.75 ml 
1.5 M Tris-HCl pH 8.8 2.5 ml -- 
1.5 M Tris-HCl pH 6.8 -- 1.25 ml 
1% (w v-1) SDS solution 1 ml 0.52 ml 
Deionized H2O 1.76 ml 2.46 ml 
25% ( w v-1) APS 20 µl 10 µl 
TEMED 20 µl 10 µl 
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4. Preparing the stacking gel according to Table 6.3. Insert a comb and pour the stacking 
gel into the casting stands, let the gel to polymerize. 
5. Preapre samples by mixing sample with sample loading buffer and boiling the mixture at 
95 °C for 10 min. 
6. Assemble the electrophoresis cell and fill the cells with running buffer. 
7. Load samples to the wells and run the gels at constant voltage of 100 V for stacking gel 
and 200 V for separating gel until the tracking dye reached the bottom of the gel.  
8. Stain the gel with blue-silver stain solution or with silver stain. 
6.3.4.1.1 Blue-silver stain 
The blue-silver stain solution consists of 0.12 % Coomassie Brilliant Blue G-250 (w v-1), 
10 % ammonium sulphate (w v-1), 10 % orthophosphoric acid (v v-1) and 20 % 
Methanol (v v-1).  The stain protocol is listed below. 
1. Wash the gel with deionized water for 10 min, repeat 3 times. 
2. Incubate the gel in Blue-silver stain solution for 4 h or overnight. 
3. Wash the gel with deionized water for 30 min. 
4. Destain the gel with deionized water till a clear background is reached. 
6.3.4.1.2 Silver stain 
All operations are completed on a rotary shaker. 
1. Incubate the gel in silver destain-fix solution for 30 min. 
2. Wash the gel with deionized water for 2 times. 
3. Incubate the gel in Farmers Reducer solution for 2.5 min. 
4. Wash gel with deionized water for 5 min. Repeat this step till the gel is colorless. 
5. Incubate the gel in 0.1 % (m v-1) silver nitrate solution for 30 min. 
6. Wash the gel with deionized water for 30 s, repeat once. 
7. Rinse the gel with 5 % (m v-1) Na2CO3 solution. 
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8. Put the gel in 100 ml 5 % (m v-1) Na2CO3 solution with 400 µl formaldehyde. Wait until 
yellow-brown bands appear. 
9. Incubate the gel in 5 % (v v-1) acetic acid for 10 min to stop the stain. 
6.3.4.2 MALDI-TOF MS 
The measurement of MALDI-TOF MS of FGF-2 was done by the group of Prof. Dr. Ulrich 
Martin at MHH, and the procedures were as follows: 1µl of sample solution was mixed 
with 1 µl 0.1 % TFA (Trifluoroacetic acid) for acidifying. Then samples were applied onto 
AnchorChip MSP 600/96 targets (Bruker Daltonik GmbH, Bremen, Germany) using α-
Cyano-4-hydroxycinnamic acid (HCCA) and 2,5-dihydroxyacetophenone (2,5-DHAP) 
(Bruker Daltonik GmbH, Bremen, Germany) as matrixes. For HCCA sample preparation, 
0.6 µl HCCA solution (2 mg ml-1) was overlaid on 1 µl of sample and dried by air; for 2,5-
DHAP sample preparation, 1 µl 2 % (w v-1) TFA and 1 µl 2,5-DHAP solution (7.6 mg ml-1) 
was overlaid on 1 µl of sample and dried by air. Two different mass measure zones were 
used, 1-10 kDa using HCCA as the matrix and 10-100 kDa using 2,5-DHAP as the matrix. 
Mass spectra reported by HCCA preparation were the results from 100-300 laser shots and 
by 2,5-DHAP preparation were the results from 2000 laser shots. MS measurements were 
performed on a Bruker Microflex LT system (Bruker Daltonik GmbH, Bremen, Germany) 
with FlexAnalysis 3.0 software (Bruker Daltonik GmbH, Bremen, Germany). Spectra were 
acquired in linear mode and mass-calibrated data acquisition methods were used. 
6.3.4.3 Western blot analysis 
Western blot analysis was accomplished by transferring protein to a polyvinylidenefluoride 
(PVDF) membrane using a Criterion Blotter (Bio-Rad, Munich, Germany) according to the 
manufacturer’s instructions. A monoclonal anti-human-FGF-2 antibody (Sigma-Aldrich, 
Taufkirchen, Germany) was used in a 1:5000 dilution. Immunoreactive bands were 
visualized by alkaline phosphatase-conjugated Goat Anti-mouse IgG (H+L) (Bio-Rad, 
Munich, Germany) followed with nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl 
phosphate (NBT/BCIP) chromogenic substrates. 
The operation procedures are listed below: 
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1. Assembling the gel into the blotting cassettes according to the instructions of the 
manufacturer.   
2. Put an ice block in the tank and fill it with transfer buffer. Then place the tank on a 
magnetic stirrer plate and stir at medium speed.  
3. Transfer the proteins at 100 V for 50 min. 
4. Blocking the membrane with block buffer for 1 h on a shaker. 
5. After blocking, without washing put the membrane in block buffer with the primary 
antibody in a 1:5000 dilution, incubating for 1 h on the shaker. 
6. Wash the membrane for 5 min with block buffer, repeat 3 times. 
7. Incubate the membrane for 1 h in TBST buffer with the secondary antibody in a 1:3000 
dilution. 
8. Wash the membrane for 3× 5 min with TBST buffer and then 2 times with TBS buffer. 
9. Wash the membrane with AP buffer for 5 min. 
10. Incubate the membrane with Color-Development-Reagent, and wait for the bands to 
appear. 
6.3.4.4 Fluorescence spectroscopy  
Fluorescence emission spectrum of FGF-2 were obtained with a HITACHI F-4500 
fluorescence spectrophotometer (HITACHI, Krefeld, Germany) using a quartz cuvette 
(Type 104.002F-QS; Hellma GmbH, Müllheim, Germany). Spectrum was obtained using 
280 nm as excitation wavelength, 10 nm slit widths and a scan speed of 240 nm min-1. 
500 µl of purified FGF-2 sample was load to the cuvette after adjusting its concentration to 
about 0.1 mg ml-1. 
6.3.4.5 RP-HPLC 
The RP-HPLC system (Merck-Hitachi La Chrome, Darmstadt, Germany) consists of an L-
7100 pump, L-7200 autosampler, D-7000 Interface Module, L-7455 diode array detector 
and L-7350 column oven. 20 µl of sample was applied to a C4 column (4.6 mm × 250 mm, 
Macherey-Nagel, Düren, Germany), equilibrated by water containing 0.1 % trifluoroacetic 
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acid (TFA). FGF-2 was eluted by a linear gradient of 0 - 50 % acetonitrile containing 0.1 % 
TFA (1 % acetonitrile min-1; flow rate 1 ml min-1). Column was at the room temperature 
and absorbance was monitored at 215 nm by the detector. The protocol is described in 
Appendix 6.5.2. 
6.3.5 Endotoxin assay 
Endotoxin content of purified FGF-2 was determined using Limulus amebocyte lysate 
(LAL) assay. The test was carried out using an Endosafe®-PTSTM system (Charles River 
laboratories, Kisslegg, Germany) with a cartridge ranging from 0.1-10 EU ml-1 and 
following the manufacturer’s instructions.  
6.3.6 Lyophilization 
Lyophilization was performed on a laboratory freezing dryer (Alpha 1-4, Martin Christ 
GmbH, Osterode am Harz, Germany). The formulated FGF-2 aliquots (2 ml in screw-caped 
tubes) were frozen at a speed of 20 °C h-1 to -25 °C and then transferred to -80 °C freezer 
frozen overnight. Primary drying was performed at a shelf temperature of -25 °C for 24 h, 
with a vacuum level less than 0.12 mbar and a condenser temperature of -60 °C. Second 
drying was carried out at a shelf temperature of + 25 °C for 12 h, the vacuum level was less 
than 0.06 mbar and the condenser temperature was the same as in the primary drying. 
Finally, the lyophilized protein was sealed under conventional atmosphere and stored. 
6.4 Bioreactor system construction and calculation 
6.4.1 Bioreactor system for fed-batch cultivation at a controlled constant 
specific growth rate 
The system consists of a 2 l bioreactor with digital control unit (Bio-Stat® B), an exhaust 
gas analyzer for measuring oxygen and carbon dioxide content in the off-gas, a PC running 
Neu-ork program for calculating the feeding pump rate and a peristaltic feeding pump. A 
diagram of the entire system could be found in Fig. 6.3. A photo of the system is shown in 
Fig. 6.4. 
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Fig. 6.3 Diagram of bioreactor and various controls of fed-batch cultivation at a constant specific 
growth rate. 
 
Fig. 6.4 Photo of the bioreactor system for fed-batch cultivation at a constant specific growth rate. 
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6.4.2 Bioreactor system for fed-batch cultivation at a constant glucose 
concentration 
The cultivation system consists of a 2 l bioreactor with digital control unit (Bio-Stat® B), an 
exhaust gas analyzer for measuring oxygen and carbon dioxide content in the off-gas, a FIA 
system for the on-line measurement of glucose concentration, a PC running EKF (extended 
Kalman filter) software for estimating state variables and calculating the pump rate and a 
peristaltic feeding pump. A diagram of the whole system is shown in Fig. 6.5. A diagram 
explains the FIA system could be found in Fig. 6.6 and a screen shot of CAFCA software 
during glucose measurement is in Fig. 6.7. A diagram of EKF is presented in Fig. 6.8 and a 
screen shot of EKF software during fed-batch cultivation is shown in Fig. 6.9. A photo of 
the whole cultivation system is shown in Fig. 6.10. 
 
Fig. 6.5 Diagram of bioreactor and various controls of fed-batch cultivation at a constant glucose 
concentration. 
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Fig. 6.6 Diagram of the FIA system. 
 
 
Fig. 6.7 Screen shot of CAFCA software during glucose measurement. 
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Fig. 6.8 Diagram of extended Kalman filter (EKF). 
 
 
Fig. 6.9 Screen shot of EKF software during fed-batch cultivation. 
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Fig. 6.10 Photo of the whole cultivation system for fed-batch cultivation at a constant glucose 
concentration. 
6.4.3 Calculations of bioreactor cultivation 
OTR (oxygen transfer rate) 
ܱܴܶ ൌ ܯைమ ∙ ܨ
௜௡
ோܸሺݐሻ ∙ ெܸ ቆݔைమ
௜௡ሺݐሻ െ ݔைమ௢௨௧ሺݐሻ ∙
1 െ ݔைమ௜௡ሺݐሻ െ ݔ஼ைమ௜௡ ሺݐሻ
1 െ ݔைమ௢௨௧ሺݐሻ െ ݔ஼ைమ௢௨௧ሺݐሻ
ቇ 
CPR (carbon production rate) 
ܥܴܲ ൌ ܯ஼ைమ ∙ ܨ
௜௡
ோܸሺݐሻ ∙ ெܸ ቆݔ஼ைమ
௢௨௧ሺݐሻ ∙ 1 െ ݔைమ
௜௡ሺݐሻ െ ݔ஼ைమ௜௡ ሺݐሻ
1 െ ݔைమ௢௨௧ሺݐሻ െ ݔ஼ைమ௢௨௧ሺݐሻ
െ ݔ஼ைమ௜௡ ሺݐሻቇ 
RQ (respiratory quotient) 
ܴܳ ൌ ܥܴܱܴܲܶ 
Here, 
ܯைమ- molecular weight of oxygen (g mol-1); 
ܯ஼ைమ- molecular weight of carbon dioxide (g mol-1); 
ܨ௜௡- the volumetric inlet air flow at standard conditions (l h-1); 
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ோܸሺݐሻ- the working volume of the bioreactor (l); 
ெܸ- the molar volume of ideal gas at standard conditions (l h-1); 
ݔைమ௜௡ሺݐሻ- the molar fractions of oxygen in the inlet air (mol mol-1); 
ݔ஼ைమ௜௡ ሺݐሻ- the molar fractions of carbon dioxide in the inlet air (mol mol-1); 
ݔைమ௢௨௧ሺݐሻ- the molar fractions of oxygen in the outlet air (mol mol-1); 
ݔ஼ைమ௢௨௧ሺݐሻ- the molar fractions of carbon dioxide in the outlet air (mol mol-1); 
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6.5 Chromatography protocols  
6.5.1 FPLC protocols  
6.5.1.1 Protocol for cation exchange membrane chromatography 
 
Step 
Time 
(min) 
System status Parameter Volume / Flow rate 
1 0:00 Zero baseline UV detector, 280 nm  
2 0:00 Isocratic flow 
A: Buffer A 100 % Volume:    10 ml 
Flow rate : 1 ml min-1 B: Buffer B 0 % 
3 10:00 
Load / Inject 
sample 
Load sample/ 
Direct inject 
Econo pump/ 
Auto inject valve 
Volume:    40 ml 
Flow rate : 1 ml min-1 
4 50:00 Isocratic flow 
A: Buffer A 100 % Volume:     30 ml 
Flow rate : 1 ml min-1 B: Buffer B 0 % 
5 80:00 Linear gradient 
A: Buffer A 100 %       0 % Volume:    30 ml 
Flow rate : 1 ml min-1 B: Buffer B 0 %       100 % 
6 110:00 Isocratic flow 
A: Buffer A 0 % Volume:    15 ml 
Flow rate : 1 ml min-1 B: Buffer B 100 % 
7 125:00 End of protocol  
 
Here, Buffer A: Equilibration buffer 
          Buffer B: Elution buffer 1 
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6.5.1.2 Protocol for heparin-sepharose affinity chromatography  
 
Step 
Time 
(min) 
System status Parameter Volume / Flow rate 
1 0:00 Zero baseline UV detector, 280 nm  
2 0:00 Isocratic flow 
A: Buffer A 100 % Volume:    10 ml 
Flow rate : 1 ml min-1 B: Buffer B 0 % 
3 10:00 
Load /Inject 
sample 
Load sample/ 
Direct inject 
Econo pump/ 
Auto inject 
valve 
Volume:    40 ml 
Flow rate : 1 ml min-1 
4 50:00 Isocratic flow 
A: Buffer A 100 % Volume:     15 ml 
Flow rate : 1 ml min-1 B: Buffer B 0 % 
5 65:00 Linear gradient 
A: Buffer A 100 %       0 % Volume:    40 ml 
Flow rate : 1 ml min-1 B: Buffer B 0 %       100 % 
6 105:00 Isocratic flow 
A: Buffer A 0 % Volume:    10 ml 
Flow rate : 1 ml min-1 B: Buffer B 100 % 
7 115:00 End of protocol  
 
Here, Buffer A: Equilibration buffer 
         Buffer B: Elution buffer 2 
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6.5.1.3 Protocol for anion exchange membrane chromatography (Endotoxin removal) 
Step 
Time 
(min) 
System status Parameter Volume / Flow rate 
1 0:00 Zero baseline UV detector, 280 nm  
2 0:00 Isocratic flow A: Buffer A 100 % 
Volume:    10 ml 
Flow rate : 1 ml min-1 
3 10:00 
Load / Inject 
sample 
Load sample/ 
Direct inject 
Econo pump/ 
Auto inject 
valve 
Volume:    25 ml 
Flow rate : 0.5 ml min-1 
4 60:00 Isocratic flow A: Buffer A 100 % 
Volume:     10 ml 
Flow rate : 1 ml min-1 
5 70:00 End of protocol  
 
Here, Buffer A: Exchanging buffer 
6.5.2 RP-HPLC protocol 
Step 
Time 
(min) 
System status Parameter Volume / Flow rate 
1 0:00 Inject sample Autosampler 20 µl 
2 0:00 Linear gradient 
A: Eluent A 100 %        50 % 
Flow rate : 1 ml min-1 
B: Eluent B 0 %        50 % 
3 0:50 Linear gradient 
A: Eluent A 50 %       100 % 
Flow rate : 1 ml min-1 
B: Eluent B 50 %       0 % 
4 0:55 Isocratic flow A: Eluent A 100 % Flow rate : 1 ml min-1 
5 0:60 End of protocol  
 
Here, Eluent A: water + 0.1 % TFA 
         Eluent B: acetonitrile + 0.1 % TFA   
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6.6 Abbreviations 
 
ANN artificial neural network  FIA flow injection analysis 
αMEM minimum essential medium, alpha 
modified 
FPLC fast protein liquid chromatography 
AP alkaline phosphatase FTIR Fourier transform infrared 
APS ammonium persulfate GC gas chromatography 
BCIP 5-bromo-4-chloro-3-indolyl 
phosphate 
GOD glucose oxidase 
BSA bovine serum albumin HCl hydrochloric acid 
CAFCA computer assisted flow control and 
analysis 
HPLC high performance liquid 
chromatography 
CPR carbon production rate IOD integration optical density 
DMEM Dulbecco's modified eagle medium iPSC induced pluripotent stem cell 
DCU digital control unit IPTG isopropyl β-D-1-
thiogalactopyranoside 
DO dissolved oxygen Km Monod substrate saturation constant 
DCW dry cell weight LAL Limulus amebocyte lysate 
DTT dithiothreitol M molar 
EC50 half maximal effective 
concentration 
MALDI-TOF matrix assisted laser desorption 
ionization-time of flight 
E. coli Escherichia coli ܯ஼ைమ molecular weight of carbon dioxide 
EDTA ethylenediaminetetraacetic acid ܯைమ molecular weight of oxygen 
EKF extended Kalman filter mM millimolar 
Em emission µ specific growth rate 
ESC embryonic stem cell µcalc calculated specific growth rate 
EU endotoxin unit µesti estimated specific growth rate 
Ex extinction µmax maximum specific growth rate 
ܨ௜௡ the volumetric inlet air flow at 
standard conditions 
µset specific growth rate set point 
FCS fetal calf serum MWCO molecular weight cut-off 
FGF fibroblast growth factor NBT nitro blue tetrazolium 
FGF-2 basic fibroblast growth factor NIR near infrared 
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Neu5Ac N-Acetylneuraminic acid TEMED N,N,N',N'-Tetramethylethylenediamine 
OD optical density  TFA trifluoroacetic acid 
OTR oxygen transfer rate TGA thermal gravimetric analysis 
pI isoelectric point Tris tris(hydroxymethyl)aminomethane 
PI proportional integral UV ultraviolet 
POD peroxidase ሶܸி feed rate 
PSA polysialic acid ሶܸி஻ feed rate of feedback part 
PSC pluripotent stem cells ሶܸிி feed rate of feedforward part 
PVDF polyvinylidenefluoride ெܸ the molar volume of ideal gas at standard 
conditions 
RISP real-time integrating software 
platform 
ோܸ culture volume 
rpm round per minute ሶܸ௦ sample flow rate of the FIA system 
RQ respiratory quotient X biomass 
S substrate concentration ݔ஼ைమ௜௡  the molar fractions of carbon dioxide in 
the inlet air 
S0 substrate concentration of feed 
solution 
ݔைమ௜௡  the molar fractions of oxygen in the inlet 
air 
Sset substrate set point ݔ஼ைమ௢௨௧  the molar fractions of carbon dioxide in 
the outlet air 
SDS-PAGE sodium dodecyl sulfate 
polyacrylamide gel 
electrophoresis 
ݔைమ௢௨௧ the molar fractions of oxygen in the 
outlet air 
SSEA4 stage-specific embryonic antigen 
4 
YA/S yield factor of acetate on glucose 
TBA thiobarbituric acid YP/S yield factor of PSA on glucose 
TCA tricarboxylic acid YX/S yield factor of biomass on glucose 
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